Podcasts about rybelsus

Novo Nordisk announced on Tuesday that it plans to cut the list prices of its blockbuster weight-loss and diabetes drugs Ozempic and Wegovy by up to fifty percent starting January first, twenty twenty-seven. The Danish company stated that various doses of these medications, which contain the active ingredient semaglutide, will drop to six hundred seventy-five dollars per month. This represents a fifty percent reduction for Wegovy and a thirty-five percent cut for Ozempic, with the same price applying to Rybelsus pills. Fox Business reports that Novo Nordisk executive Jamey Millar explained the move aims to help more than one hundred million Americans with obesity and thirty-five million with type two diabetes by lowering out-of-pocket costs, especially for those on high-deductible health plans. CBS News notes this comes amid fierce competition from rivals like Eli Lillys Mounjaro and Zepbound, as well as cheaper compounded versions from telehealth providers. The price slash will align with lower Medicare rates for older Americans but will not affect direct-to-consumer prices, where Wegovy already sells for three hundred forty-nine dollars.In related news, Oprah Winfrey has shared fresh insights on her use of GLP-one medications like those in the Ozempic family. In a recent NBC Connecticut discussion tied to her book Enough, co-authored with Yale Obesity Research Center director Doctor Ania M. Jastreboff, Winfrey reflected on stopping the shots cold turkey on her seventieth birthday in January twenty twenty-four after gaining clarity that obesity drives overeating due to the bodys enough point, a genetically influenced weight set point. She tried maintaining her loss through diet and exercise alone but regained twenty pounds over twelve months, realizing these drugs are a lifelong tool, much like blood pressure medication. Doctor Jastreboff emphasized in the interview that the medications recalibrate this enough point in the brain, reducing hunger signals and fat storage, countering the bodys drive to regain weight. Winfrey, who pays out of pocket for friends unable to afford the shots, urges ending shame around obesity, calling it a disease not a personal failing. She stresses combining drugs with healthy habits for sustainable health, not just looks.These developments highlight growing accessibility and realism around GLP-one drugs amid evolving expert views.Thanks for tuning in, listeners, please subscribe, come back next week for more, and remember this episode was brought to you by Quiet Please podcast networks. For more content like this, please go to Quiet Please dot Ai.Some great Deals https://amzn.to/49SJ3QsFor more check out http://www.quietplease.aiThis content was created in partnership and with the help of Artificial Intelligence AI

It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: big updates for stem cell and islet transplants, new pen option for Zepbound, an implantable insulin pump moves forward and more! Announcing Community Commericals! Learn how to get your message on the show here. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Omnipod - Simplify Life All about Dexcom  T1D Screening info All about VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Episode transcription with links: Welcome! I'm your host Stacey Simms and this is an In The News episode.. where we bringing you the top diabetes stories and headlines happening now. A reminder that you can find the sources and links and a transcript and more info for every story mentioned here in the show notes. Quick reminder: I'm just back from MNO DC and I'm exhausted. But it's the best kind of tired. We had an incredible time – hope you can join us in Nashville. With a reminder that we have our first Club 1921 in Nashville – that's our educational dinner series for HCPs and patient leaders. All the info is over at diabetes-connections.com events/     Okay.. our top story this week: XX An "immune system reset" eliminated Type 1, diabetes in mice in a study conducted at Stanford Medicine without immune suppressant medications. This was a combined transplant of blood stem cells and insulin-producing pancreatic islet cells from a donor whose immune profile did not match the recipient. The dual transplant approach both restored insulin production and retrained the immune system. For the full six months of the experiment, the animals did not need insulin injections or immune suppressive medications. Challenges remain using this approach to treat Type 1 diabetes. Pancreatic islets can be obtained only after death of the donor, and the blood stem cells must come from the same person as the islets. It is also unclear whether the number of islet cells typically isolated from one donor would be enough to reverse established Type 1 diabetes. But the researchers are working on solutions, which could include generating large numbers of islet cells in the laboratory from pluripotent human stem cells, or finding ways to increase the function and survival of transplanted donor islet cells. https://scitechdaily.com/stanford-scientists-cure-type-1-diabetes-in-mice-without-insulin-or-immune-suppression/ XX An electronic implant interlaced with islet cells is being looked at to treat type 1. Researchers at the University of Pennsylvania School of Medicine worked with engineers at Harvard University to combine stem-cell biology with soft electronics. They inserted an ultrathin, flexible mesh of conductive wires — thinner than a human hair — into developing pancreatic tissue. As the cells assembled into clusters, the mesh became woven through them. The electronics can record the faint electrical signals produced by the cells that control insulin release. They can also deliver small pulses of electricity back to the cells.   After several days, the cells began to behave more like mature islets. Their internal signalling shifted, neighbouring cells started working in concert and insulin release became stronger and better timed.  Very early on here – and the transplanted cells still need to be protected from being attacked by the immune system. https://www.thetimes.com/uk/science/article/first-cyborg-pancreas-implants-type-1-diabetes-nxkv8r0fp?gaa_at=eafs&gaa_n=AWEtsqeJYYUF9TMR-GgGUG92hPyog-ISeiqGIgdyaaIKKcpvhtoftGiUaaOtQeG0NWI%3D&gaa_ts=699c50d4&gaa_sig=w-PQ0ArosZSznYDSWEzt8aQg4WC0FF5ZFRt9NedO5sSTL2FyWzupH8eSG7RCy2S8TQnlHOeKCudANWm1MNI59w%3D%3D XX Katie Beth (hand) Eledon trial – aaron kowalski post linkedin. Last fall we told you about promising results from Eledon's drug to prevent islet transplantation rejection in type 1 diabetes. The first six patients no longer had to inject or infuse insulin.. the trials continue and this month one of the patients – Katie Beth Hand – began posting about her experiences one month in, on social media, she says she's off basal insulin already and in range 99 percent of the time. She is also encouraging people to learn more about support the islet act https://lnkd.in/e8pQ7_Y7 XX This is a bill introduced last November which would change the wording on pancreatic cell transplants. The problem is that islets are classified as drugs rather than organs, making transplantations difficult for medical teams and centers to preform due to accessibility. Insurance companies are also less likely to provide reimbursements for treatment, which can cost hundreds of thousands of dollars. The official Journal of The Transplantation Society estimates the cost at about $140,000. The bill went to the senate committee of Health, Education, Labor, and Pensions in early November. No other action has been taken since then. https://www.wtoc.com/2026/02/19/bluffton-family-advocates-islet-act-help-diabetic-son/ XX Big change for the obesity drug Zepbound – now available in the multi dose KwikPen. This is a month's worth of doses in a single pen.. and it's multi dose – you can adjust it. Cash-paying patients can get the multi-dose device, called KwikPen, on the company's direct-to-consumer website, LillyDirect. Prices start at $299 per month for the lowest dose level. Until now, you could only get zepbound in a single dose auto injector or a sing dose vial. In a release, Lilly said the Food and Drug Administration approved a label expansion for Zepbound to include the multi-dose device. The KwikPen is already used for other drugs, such as Lilly's popular diabetes medication, Mounjaro – which is the same medication as zepbound, they're both tirzepitide. https://www.cnbc.com/2026/02/23/eli-lilly-launches-zepbound-obesity-drug-pen-one-month-doses.html   XX For years, researchers have observed that people who live at high elevations,  tend to develop diabetes less often than those at sea level. Although the trend was well documented, the biological explanation behind it was unclear. Scientists now say they have identified the reason. Their research shows that in low oxygen environments, red blood cells begin absorbing large amounts of glucose from the bloodstream. Their work showed that when oxygen is limited, red blood cells use glucose to generate a molecule that helps release oxygen to tissues. This process becomes especially important when oxygen is in short supply. The researchers also found that the metabolic benefits of prolonged hypoxia lasted for weeks to months after mice were returned to normal oxygen levels. They then evaluated HypoxyStat, a drug recently developed in Jain's lab that mimics low oxygen exposure. HypoxyStat is taken as a pill and works by causing hemoglobin in red blood cells to bind oxygen more tightly, limiting the amount delivered to tissues. In mouse models of diabetes, the medication completely reversed high blood sugar and outperformed existing treatments. https://www.sciencedaily.com/releases/2026/02/260221060952.htm XX Watching this one closely – Portal Diabetes gets FDA breakthrough device designation for its implantable insulin pump system. This is a system that includes not just a device that's implanted into the abdomen, but also a new, temperature stable insulin. It will work with – quote – "modern" CGM technology with a fully closed loop - and aims to deliver a functional cure for type 1. While reports say Portal's system is the first in the US – there was an implantable pump developed and used by about 500 people worldwide, including about 100 in the US – by MiniMed. Medtronic bought the company and in 2007 they stopped that program. Portal Diabetes expects to begin clinical trials on its combination system around the fourth quarter of 2027. https://www.drugdeliverybusiness.com/portal-diabetes-fda-breakthrough-implantable-insulin-pump/ XX Sequel Med Tech and Senseonics (NYSE:SENS) today announced the full U.S. launch of their CGM and insulin pump integration. That's the eversense cgm and twist pump. Sequel said its full launch with Eversense 365 makes twiist available with two compatible CGMs. twiist also pairs with the Abbott FreeStyle Libre 3 Plus sensor. Eversense 365, an implantable system, rests under the skin for the duration of a year. Users can change its external, silicone-based adhesive daily with almost no skin reactions. https://www.drugdeliverybusiness.com/sequel-senseonics-full-launch-twiist-eversense/ XX Right back with a Dexcom update, and a look at which type of diet reduces insulin use overall.. right after this: -- Back to the news.. Dexcom is watching for expanded Medicare coverage of its continuous glucose monitors to people with Type 2 diabetes who don't take insulin. CEO Jake Leach told investors on Thursday that the company has been "sitting here waiting for a coverage decision" from the Centers for Medicare and Medicaid Services Dexcom started to see commercial coverage unlock for Type 2, non-insulin users toward the end of last year, Leach said. He expects broader Medicare coverage for that group would allow nearly 12 million people to access CGMs.     In the meantime, the American Diabetes Association updated its guidelines last year to recommend clinicians consider using CGMs for Type 2 diabetes when patients are taking glucose-lowering medications other than insulin. Leach said that real world data the company has been generating supports that decision, and that Dexcom has launched a registry for non-insulin users. https://www.medtechdive.com/news/dexcom-seeks-expanded-medicare-coverage-of-cgms-for-type-2-diabetes/812223/ XX Medtronic's separation of MiniMed is not yet complete.. but continues to move forward. The company has submitted their next pump – MiniMed Flex – to the FDA. This is a pump smaller than the 780G but uses the same reservoirs and infusion sets. It will also work with both the Simplera Sync and Instinct sensors. Medtronic also began a U.S. pivotal study for Vivera, its third-generation algorithm for automated insulin delivery. It also remains set to submit its MiniMed Fit patch pump system to the FDA by the coming fall. https://www.drugdeliverybusiness.com/medtronic-submits-minimed-flex-fda-q3/ XX A study modelling how genes may influence a child's body mass index over time has found that BMI at age 10 and overall growth rate between ages one and 18 might be important factors, as the two are more likely linked to diabetes, high cholesterol, and heart disease in later life. Nearly 66,000 BMI measurements from around 6,300 children and adolescents aged one to 18 were analysed to understand the role of genes.     "Future research is needed to help identify the most effective ages to prevent obesity or poor growth for long-term benefit." https://www.ndtv.com/health/bmi-at-age-10-growth-rate-up-to-age-18-are-important-factors-for-diabetes-heart-disease-study-11125146 XX A low-fat vegan diet—without cutting calories or carbs—may help people with type 1 diabetes significantly reduce how much insulin they need. In a new analysis published in BMC Nutrition, participants following the plant-based plan lowered their daily insulin use by 28%, while those on a portion-controlled diet saw no meaningful change. Researchers say the reduced insulin requirement likely reflects improved insulin sensitivity. The original 2024 study reported additional benefits from the vegan diet. Participants lost an average of 11 pounds and showed improvements in insulin sensitivity and glycemic control. Cholesterol levels and kidney function also improved among those following the plant-based plan. https://www.sciencedaily.com/releases/2026/02/260212234212.htm XX Interesting little tidbit from the Winter Olympic Games.. the World Anti-Doping Agency (WADA) was monitoring GLP drug use. An advisory group that makes recommendations about WADA's list of prohibited substances discussed the status of GLP-1 medications, and added semaglutide (Ozempic, Wegovy, Rybelsus) and tirzepatide (Mounjaro, Zepbound) to its monitoring program That means patterns of use of these drugs will be tracked both in and out of competition.  The finding will be used to make recommendations about whether GLP-1 agonists should be added to the prohibited list, the spokesperson explained. While GLP-1 drug use is not currently prohibited, that could change before the next Summer Olympic Games in Los Angeles in 2028, he noted. https://www.medpagetoday.com/popmedicine/cultureclinic/119770 XX That's it for in the news!

Welcome to Ozempic Weightloss Unlocked, where we dive into the latest news on Ozempic from medical breakthroughs to real-life health impacts.Recent Cochrane reviews commissioned by the World Health Organization show that Ozempic, or semaglutide, leads to about eleven percent average weight loss after six to eighteen months in people with obesity, outperforming placebo in eighteen trials with nearly twenty-eight thousand participants. Tirzepatide, like Mounjaro, achieves even more at sixteen percent, while liraglutide offers four to five percent. These glucagon-like peptide-one drugs mimic a hormone that slows digestion and boosts fullness, originally for type two diabetes but now key for weight management with diet and exercise.Cochrane researchers note benefits persist during treatment but highlight gaps: most trials were industry-funded, long-term safety data is limited, and side effects like nausea affect many, with some dropping out. No clear edge on heart events or death versus placebo yet.A Rutgers Health study in the Journal of Medical Internet Research analyzed sixty online reviews and found sixty-seven percent of users report weight loss, less appetite, or fewer cravings, making them stick with it despite nausea or vomiting in sixty-two percent. Lead author Abanoub Armanious says everyday experiences show benefits often outweigh gut issues for motivated users. Bariatric expert Mir Ali adds diarrhea or pain prompts more quits than nausea.Newer buzz includes Ozempic face: rapid fat loss causes gaunt cheeks, per a Gujranwala Medical College analysis and American Academy of Facial Plastic and Reconstructive Surgery survey, boosting filler demand by fifty percent. Weight regain post-treatment is common, stressing lifestyle pairing.Wegovy now offers semaglutide pills like Rybelsus, matching injections for seventeen percent loss with changes, per Prisma Health's Eva Wolf.Listeners, blend these tools with habits for lasting wins. Thanks for tuning in—subscribe for more updates. This has been a Quiet Please production, for more check out quietplease.ai. Some great Deals https://amzn.to/49SJ3QsFor more check out http://www.quietplease.aiThis content was created in partnership and with the help of Artificial Intelligence AI

Arecor Therapeutics PLC's (AIM:AREC) CEO Sarah Howell talked with Proactive's Stephen Gunnion about the company's second-half performance and its strategic priorities heading into 2026, highlighting progress across its dual focus on diabetes and oral peptide delivery. Howell explained that Arecor is a clinical-stage biopharmaceutical company focused on drug development and enhanced delivery in the cardiometabolic space. The company's lead asset, AT278, is described as a “new unique best-in-class ultra-concentrated (500 U/mL) and ultra-rapid-acting insulin for the treatment of diabetes,” and is now progressing through a 50:50 co-development partnership with Sequel Med Tech. The collaboration is preparing for a pivotal phase two clinical study, which Arecor is targeting to begin in the second half of 2026. She noted that both teams share a vision of combining next-generation automated insulin delivery (AID) systems with next-generation insulin to improve patient outcomes and reduce disease management burden. Positive negotiations are also underway regarding a broader co-development and commercialisation partnership. On the oral GLP-1 programme, Howell highlighted the challenge of bioavailability, pointing out that Rybelsus (semaglutide), an oral GLP-1 tablet for adults with type 2 diabetes, currently achieves “less than 1% oral bioavailability.” Arecor is conducting nonclinical pharmacokinetic studies aimed at improving bioavailability, which could be highly translatable across multiple peptide therapeutics. Financially, the company reported unaudited revenues of £3.1 million for 2025 and cash of £6.1 million at year-end, extending the runway into the first half of 2027. For more insights into Arecor Therapeutics PLC's strategy and upcoming milestones, visit Proactive's YouTube channel, like this video, subscribe to the channel and enable notifications so you never miss future updates. #ArecorTherapeutics #SarahHowell #AT278 #DiabetesTreatment #InsulinInnovation #OralGLP1 #GLP1 #PeptideTherapeutics #BiotechNews #ClinicalTrials #Phase2Trial #MedTech #Cardiometabolic #HealthcareInnovation #ProactiveInvestors

It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: T1D in the Olympics & Superbowl, Trump RX goes live, Ozempic pill available soon, tech updates from Medtronic, Beta Bionics, Eversense 365 and more! Announcing Community Commericals! Learn how to get your message on the show here. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Omnipod - Simplify Life All about Dexcom  T1D Screening info All about VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Episode transcription with links: Welcome! I'm your host Stacey Simms and this is an In The News episode.. where we bringing you the top diabetes stories and headlines happening now. A reminder that you can find the sources and links and a transcript and more info for every story mentioned here in the show notes. Quick reminder: We are just over one week from our first Moms' Night Out event of the year. While the plans are all set – the speakers, the vendors, the raffles and the fun is ready to go, it's always amazing how many people hear of these event last minute. That's fine, they're welcome! But if you're thinking of attending a future event – registration is open for We're going to Nashville next March 6-7 and Detroit in September – no need to wait. And we've got Club 1921 events for health care professionals and patient leaders in 6 cities this year! All the info is over at diabetes-connetionss.com events/   Okay.. our top story this week: XX Gotta be a quick shout out to some incredible T1D athletes – we had TWO in the super bowl this past weekend – Chad Muma of the New England Patriots and Logan Brown of the Seattle Seahawks AND there are at least two athletes with type 1 competing at the Winter Olympics. Hannah Schmidt competes in ski cross for Canada – she was diagnosed with Type 1 diabetes at age 12 years old.  Anna FarnSchadt Fernstäd a Czech skeleton racer diagnosed in 2022 after she'd already been to several Olympics. We wish them all the best!   https://english.radio.cz/skeleton-racer-anna-fernstadtova-overcoming-adversity-headfirst-down-ice-8876699 XX The government website TrumpRx.gov is live..  the website does not sell prescription drugs. Instead, it allows people to look up their drugs and then navigate to buy them elsewhere, either from a major drug company or a pharmacy. The 43 drugs listed on the site have prices ranging from $3 to over $5,500. TrumpRx does include warnings that the site may not be the best option to save money on prescriptions. Each product page advises: "If you have insurance, check your co-pay first — it may be even lower." For now, the website says its prices are for people paying with their own money, rather than going through insurance. The only insulin listed right now is Lilly's insulin lispro – and it's the same price as you'd find through Illy's insulin value program. I looked up diabetes meds.. For example, if you have an insurance co-pay of $25 a month for Farxiga, a drug often used for diabetes, you would be paying $182 on TrumpRx. As you can imagine, though ,this is complicated and as with most of our healthcare system, it may be good in some cases and not much help in other.  I'd suggest calling your local pharmacist or checking with your human resource dept. https://www.nytimes.com/2026/02/06/health/trumprx-prescription-drug-prices-consumers.html XX Novo Nordisk will launch some doses of its oral semaglutide for diabetes under the brand name Ozempic pill in the second quarter of this year. The company said the U.S. Food and Drug Administration has approved Ozempic tablets in three different doses. Novo says The new Ozempic name is intended to help patients and health care professionals more easily recognize the available treatment options for type 2 diabetes Semaglutide tablets have been available under the brand name Rybelsus Ruh BELL sis for diabetes since 2019 but with different dosing. The pill is also approved to reduce the risk of certain cardiovascular conditions in adults with type 2 diabetes who are at high risk for these events. The FDA had approved the new doses based on a bioequivalence study and the clinical trial data for Rybelsus, Novo said. https://www.reuters.com/business/healthcare-pharmaceuticals/novo-launch-ozempic-pill-diabetes-second-quarter-this-year-2026-02-04/ XX https://www.contemporarypediatrics.com/view/early-screening-for-type-1-diabetes-found-effective-in-children XX Possible new way to identify and track the progress of type 1 diabetes before clinical onset. A recent study published in Science Advances described the application of subcutaneous microporous scaffolds. These are inserted and have been shown to  identify changes in cancer, multiple sclerosis, and T1D by capturing changes of immune cells over the course of a disease. This is a proof of concept study in mice.. so very early days. https://www.news-medical.net/news/20260204/Implantable-immune-scaffold-predicts-type-1-diabetes-weeks-before-symptoms.aspx XX A large global genetics study shows that many key drivers of Type 2 diabetes operate outside the bloodstream. In a major international project led in part by the University of Massachusetts Amherst and Helmholtz Munich in Germany, researchers linked hundreds of genes and proteins to the disease. The work, published in Nature Metabolism, points to a key challenge in diabetes research: the biology behind rising blood sugar does not play out the same way in every part of the body. It also shows why including people from many backgrounds matters, since genetic clues that stand out in one population may be faint or invisible in another. Huge study, 2.5 million people worldwide comparing patterns across seven tissues tied to diabetes and four global ancestry groups, then asked a simple question: what do you miss if you only measure blood? Across the seven tissues, the researchers found causal evidence pointing to 676 genes. Yet overlap with blood was limited: only 18% of genes with a causal effect in a primary diabetes tissue, such as the pancreas, showed a matching signal in blood. At the same time, 85% of genetic effects observed in diabetes-relevant tissues were completely absent from blood-based analyses. The findings lay out a roadmap for future research aimed at understanding the biological pathways underlying Type 2 diabetes and developing more effective treatments. https://scitechdaily.com/massive-global-study-rewrites-the-biology-of-type-2-diabetes/ XX Express Scripts settled the U.S. Federal Trade Commission's claims its insulin pricing practices violated antitrust and consumer protection laws, and agreed to changes aimed at lowering costs for patients, insurers and small pharmacies The settlement, first reported by Reuters, fits with that goal, and allows the FTC to pare down a case brought by the former Biden administration against Cigna's Express Scripts, UnitedHealth Group Inc's (UNH.N), Optum unit and CVS Health Corp's (CVS.N), CVS Caremark. The case against Optum and Caremark is ongoing. Pharmacy benefit managers, which set how drugs are covered by health insurance, have faced a decade of scrutiny from regulators and lawmakers over pricing practices. While the industry has already made reforms, the settlement gives the FTC power to enforce broader changes at Express Scripts. The 10-year agreement restricts Express Scripts' ability to engage in practices critics say contribute to high costs, like pocketing rebate payments from drugmakers based on the list price of drugs. The FTC estimates the agreement could save patients as much as $7 billion over a decade. https://www.reuters.com/world/cigna-settles-ftc-insulin-case-commits-overhauling-drug-pricing-2026-02-04/ XX Audio? Congress has passed bipartisan legislation to extend and strengthen the Special Diabetes Program (SDP), a cornerstone of Federal investment in type 1 diabetes (T1D) research. The President signed the legislation and it is now law. Extends the SDP through December 31, 2026, and increases funding from $160 million to $200 million annually. Strengthens overall funding for the National Institutes of Health (NIH) by $415 million. Increases diabetes research funding at the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) by $10 million. Created by Congress and administered by the NIH, the SDP has contributed nearly $3.6 billion to T1D research and has played a role in nearly every major breakthrough in the field. A recent study conducted by Avalere Health shows that of the nearly 3.6 billion invested into the SDP by Congress since the establishment of the program, the Federal Government has realized $50 billion in healthcare savings through improved health outcomes from the use of SDP driven therapies and devices https://www.breakthrought1d.org/news-and-updates/congress-passes-bipartisan-extension-of-the-special-diabetes-program-securing-critical-t1d-research-funding/ XX Dexcom is rolling out what they're calling AI-enabled enhancements to Stelo, further transforming how users track and understand their glucose health. Expanded Smart Food Logging including a comprehensive nutrition database of more than 1M meals that provides a breakdown of calories, carbohydrates, protein, fat, dietary fibers, and more. More ways to meal track including text search, barcode scanning or taking a photo of the meal, creating a seamless and intuitive meal tracking solution. A redesigned Daily Insights feature which will introduce a new interface with more personalized recommendations. The newest features will launch nationwide in the coming weeks.  XX Beta Bionics has received a warning letter from the Food and Drug Administration following an inspection last year, the company disclosed on Friday. The diabetes technology company said in a securities filing that the warning letter concerns non-conformities with the company's quality management system, medical device reporting, and correction and removals. The warning letter has not yet been posted by the FDA.   The company said in the filing that it has already taken actions to improve the processes described in the warning letter, and it is working on a written response to the FDA.   The firm does not expect the warning letter to affect the planned launch of a new insulin patch pump by the end of 2027. Beta Bionics unveiled a prototype of the device, called Mint, last year at the American Diabetes Association's Scientific Sessions. The company also does not expect the warning letter to affect its financial results. https://www.medtechdive.com/news/beta-bionics-receives-fda-warning-letter/811140/?utm_source=Sailthru&utm_medium=email&utm_campaign=Issue%3A+2026-02-04+MedTech+Dive+%5Bissue%3A81423%5D&utm_term=MedTech+Dive&fbclid=IwY2xjawPwhDZleHRuA2FlbQIxMABicmlkETFaUUcyYmNQWldjZ2xudElic3J0YwZhcHBfaWQQMjIyMDM5MTc4ODIwMDg5MgABHouF8M3IstTyslPRgeHWUWVVdOAGOtzPWt_yNFcj9eYruqSPz3e86Iwcbpt8_aem_7q4D97vJVjHKfEwvoyUpgw XX Sequel Med Tech is reviewing co-founder Dean Kamen's ties to Jeffrey Epstein after recently released documents revealed new details about the longstanding relationship between the two men. The documents show that Kamen visited Epstein's island, and remained in contact with him for years after Epstein was convicted of sex crimes involving minors. Kamen has not been accused of any wrongdoing. In a statement, Sequel Med Tech said the Manchester-based company is aware of the documents pertaining to Kamen and – quote - "Sequel's Board of Directors has unanimously decided to engage an external law firm to review these disclosures and provide recommendations aligned with our mission to serve people living with diabetes," Kamen has not issued a statement regarding his reported connection to Epstein.   https://www.bostonglobe.com/2026/02/04/metro/nh-dean-kamen-jeffrey-epstein-review/ https://www.bostonglobe.com/2026/02/04/metro/nh-dean-kamen-jeffrey-epstein-review/ https://www.nbcboston.com/news/local/nh-inventor-placed-on-leave-after-epstein-messages-surface-report-says/3888569/ XX Abbot reports 860 serious injuries linked to the recall of some of its glucose monitoring sensors. We told you about this recall late last year, these numbers are an FDA update.     Abbott said the sensors can provide incorrect glucose readings over extended periods, which could lead to users making dangerous treatment decisions, including eating excessive carbohydrates along with skipping or delaying insulin doses, potentially leading to serious health risks. The company said it has identified and resolved the cause of the issue, which relates to one production line among several that make Libre 3 and Libre 3 Plus sensors.   https://www.reuters.com/business/healthcare-pharmaceuticals/abbott-recalls-glucose-sensors-after-seven-deaths-linked-faulty-readings-2026-02-04/ XX Updates from Medtronic & Senseonics – and a first from Nick Jonas.. right after this..   I'm excited to share that the FDA has cleared the MiniMed 780G system with the Instinct sensor, made by Abbott, for people with type 2 diabetes.  Medicare has also now approved coverage for the Instinct sensor for use with the MiniMed 780G system. This clearance and expanded coverage mean more people will have access to pairing our most advanced automated insulin delivery technology with the Instinct sensor, that offers a smaller, 15-day sensor experience.  They're also launching the MiniMed 780G system Pump Evaluation Program.  This program gives individuals living with diabetes the ability to try the full MiniMed 780G system at no cost for 30 days.† This includes the pump, the sensor of their choice, one month of infusion sets and reservoirs, everything but the insulin. They'll contact your doctor for you to get a prescription and get the process rolling. https://www.medtronicdiabetes.com/pump-evaluation-program XX Senseonics announced today that its Eversense 365 continuous glucose monitor (CGM) system received CE mark approval – that's European clearance.  This comes on the heels of the launch of Eversense 365 with Sequel Med Tech's twiist pump, marking the first pump integration for the CGM. Senseonics plans to launch Eversense 365 in Germany, Italy, Spain and Sweden in the coming months. Meanwhile, Senseonics continues to work toward an FDA investigational device exemption (IDE) submission for its next-generation Gemini transmitter-less CGM by the end of this year. https://www.drugdeliverybusiness.com/senseonics-ce-mark-eversense-365-cgm/ XX A huge shout out to Dr. Emily Blum, who just accomplished riding 100 miles in Antarctica for Breakthrough T1D! Despite having no direct connection to Type 1 Diabetes, Emily has been riding and fundraising for BreakthroughT1D for 10 years now. She is an integral part of the Georgia Ride team, training and riding many miles, and most importantly has raised tens of thousands of dollars to support the cause of ridding the world of T1D. She is surgeon and deeply involved with medical innovation, with an incredibly busy schedule, but jumped at the chance to take on the challenge of riding a century on every continent. Having already completed North America, Europe, Australia, Asia, and now Antarctica, only Africa and South America remain. Emily rides on and continues to be an inspiration to everyone who meets her. XX   https://diabetes-connections.com/t1d-connection-and-people-magazine-elise-zach-share-their-story/ XX Nick Jonas's becomes the first artist ever to wear a CGM on an album cover - new upcoming solo album Sunday Best, releasing Feb. 6.  The release says: This marks a powerful step forward in normalizing diabetes and raising awareness for the condition on a global scale. This moment adds to the growing visibility of diabetes in pop culture, alongside milestones like a Type 1 diabetes Barbie and Pixar characters wearing diabetes technology.

Wegovy Pill: Who's It For?The new Wegovy pill is generating massive buzz — but is it actually better than the injection? Before you ask your doctor to switch, there are some surprising requirements that could make or break whether this option works for you.This week on Fat Science, Dr. Emily Cooper, Mark Wright, and Andrea Taylor break down the new oral semaglutide approved for obesity treatment. They explain how the Wegovy pill differs from Rybelsus, who's a good candidate to switch (and who isn't), the strict dosing protocol most people don't know about, and what's coming next in the GLP-1 pill landscape — including a less fussy competitor from Eli Lilly.Key TakeawaysThe Wegovy pill uses an upgraded "version two" formulation with enhanced absorption — it's not the same as RybelsusSemaglutide targets deep metabolic dysfunction, not just appetite — reducing inflammation, visceral fat, and cardiovascular riskThe pill must be taken first thing in the morning on an empty stomach with minimal water, then nothing else for 30 minutes — breaking this protocol negates effectivenessThe pill is slightly less effective than the highest-dose Wegovy injection, so switching isn't ideal for patients still making progress at maximum doseNovo Nordisk's cash pay program starts at $149/month for lower doses and $299/month for the highest doseEli Lilly's upcoming orforglipron pill uses small molecule technology that won't require the strict dosing ritualNotable Quote"When people say it works because it just makes you eat less, that's really missing the point of the sophistication of these meds." — Dr. Emily CooperLinks & ResourcesPodcast Home: fatsciencepodcast.comCooper Center for Metabolism: coopermetabolic.comResources from Dr. Cooper: coopermetabolic.com/resourcesJoin Our Community: patreon.com/cw/FatSciencePodcastSubmit Your Question: questions@fatsciencepodcast.com or dr.c@fatsciencepodcast.comFat Science is supported by the Diabesity Institute, a nonprofit dedicated to increasing access to effective, science-based metabolic care.Disclaimer: This podcast is for informational purposes only and is not intended as medical advice. Please consult with a qualified healthcare provider for personalized recommendations.

Send a Text Message. Please include your name and email so we can answer you! Please note, this does not subscribe you to our email list, it's just to answer if you have a questions for us. We finally have the first-ever FDA-approved oral GLP-1 for treating obesity, and it's a much bigger deal than the headlines suggest…In this episode, I'm joined by Joseph Zucchi, PA, a clinical supervisor at a weight management clinic who lives and breathes the data behind obesity care. We break down oral Wegovy in practical terms: the real weight loss data, how it compares with weekly injections, why it's different from Rybelsus, and who it's best suited for. We also cover cost, insurance disruptions, and what to realistically expect if you're considering a switch.If you're trying to make sense of your options in a fast-changing landscape, whether due to coverage changes, injection concerns, or simple confusion — this conversation helps break it all down using real data.ReferencesConnect with Joseph Zucchi, PATransition Medic Medical Weight LossLinkedinAudio Stamps01:42 – Meet Joseph Zucchi, PA, clinical supervisor at a comprehensive weight management clinic with an on-site food store.04:35 – What is oral Wegovy and how does it compare to injectable semaglutide in terms of efficacy and weight loss?07:21 – The reformulation that makes oral Wegovy different from Rybelsus and why absorption matters.10:22 – How to take oral Wegovy correctly: timing, dosing instructions, and common mistakes to avoid.12:02 – Who should consider oral Wegovy and who might be better off sticking with injections?13:45 – Side effects, dosing transitions, and what to expect when switching from injectable to oral.22:03 – The importance of specialized care: why working with a weight management expert improves outcomes.24:00 – Pricing, insurance coverage challenges, and accessibility of oral Wegovy in 2026.All of the information on this podcast is for general informational purposes only. Please talk to your physician and medical team about what is right for you. No medical advice is being on this podcast. If you live in Indiana or Illinois and want to work with doctor Matthea Rentea, you can find out more on www.RenteaClinic.com Not Sure Where to Start With the Podcast? I've Got You.Get my free Podcast Roadmap—a simple guide to help you find the episodes that matter most to your journey. Whether you're on GLP-1s, navigating plateaus, or just starting out, there's something here for you.Support the show

Health Canada approved the first glucagon-like peptide one daily pill, Rybelsus, on Monday for adults with type two diabetes who face high risks of heart disease. This semaglutide pill, made by the same company behind injectable Ozempic and Wegovy, aims to improve blood sugar levels alongside diet and exercise while cutting chances of heart attacks, strokes, or death from cardiovascular events. Company trials with over nine thousand six hundred fifty patients showed it lowered those risks compared to a placebo. Unlike prior GLP one drugs in Canada, all injectables until now, this offers a convenient oral option, though experts note it may need higher doses since stomach acids break down some of the peptide, making injections potentially more effective for weight loss.Recent studies highlight challenges with these medications. A review in the British Medical Journal, published this week, analyzed sixty-three trials involving more than nine thousand people and found users regain weight at about zero point four kilograms per month after stopping GLP one drugs, with heart benefits vanishing too. In the United States, the food and drug administration approved an oral Wegovy pill last month, now available for around one hundred forty-nine United States dollars monthly through places like Amazon Pharmacy.Oprah Winfrey, seventy-one, shared candid thoughts on GLP one medications this week during appearances on CBS Sunday Morning and The View. She called them a vital tool for managing obesity, a disease she now views without shame or self-blame. Winfrey said the constant food noise in her mind vanished hours after her first dose, freeing her from obsession despite still enjoying food. She regrets not discovering them in two thousand thirteen, lamenting wasted years of sadness, and admitted gaining twenty pounds in a year after stopping to test her willpower, proving to her it is a lifelong need like blood pressure medicine. Promoting her new book with doctor Ania Jastreboff, she stressed obesity causes overeating, not the reverse, and urged ending blame, even covering costs for friends who cannot afford it.Analysts at Jefferies noted on January twelfth that widespread use of weight loss drugs like Ozempic could save major United States airlines up to five hundred eighty million dollars in fuel this year, as lighter passengers cut jet fuel needs by up to one point five percent. In Canada, semaglutide patents expired this month, paving the way for cheaper generics to boost access.Thanks for tuning in, listeners, please subscribe, come back next week for more, and remember this episode was brought to you by Quiet Please podcast networks. For more content like this, please go to Quiet Please dot Ai.Some great Deals https://amzn.to/49SJ3QsFor more check out http://www.quietplease.aiThis content was created in partnership and with the help of Artificial Intelligence AI

In this episode of Healthy Mom Healthy Baby Tennessee, Dr. Linley Wolfe interviews Dr. Carrie Brackney, a maternal-fetal medicine physician in Memphis, about GLP-1 receptor agonist medications (commonly known as Ozempic, Wegovy, and similar drugs) and their implications for pregnancy. The discussion covers how these medications work, their dramatic effects on weight loss and diabetes management, and the emerging phenomenon of "Ozempic babies" - unintended pregnancies occurring in women taking these medications. Dr. Brackney provides guidance on when to discontinue these medications before conception, discusses limited safety data in pregnancy, and explains what monitoring is recommended for women who become pregnant while taking GLP-1s. Both physicians share their personal experiences with these medications and express hope for future research on postpartum use.Episode Highlights00:00:04: Welcome to Healthy Mom, Healthy Baby Tennessee podcast, brought to you by the Tennessee Initiative for Perinatal Quality Care (TIPQC), which exists to improve health outcomes for mothers and infants in Tennessee 00:00:46: Dr. Linley Wolfe introduces Dr. Carrie Brackney, a maternal-fetal medicine physician in Memphis who has been practicing as a perinatologist for three years after working as a general OB-GYN for nine years00:01:32: Dr. Brackney describes her passion for caring for women with complex pregnancies and helping them find joy during challenging times00:02:03: Dr. Wolfe introduces the topic of GLP-1 medications, noting they have been revolutionary for people struggling with weight00:02:38: Dr. Brackney explains that GLP-1 receptor agonists work by activating glucagon-like peptide one receptors, regulating blood sugar, reducing appetite, and slowing digestion through multiple mechanisms00:03:46: Discussion of how GLP-1 medications have been around for diabetes treatment but have been increasingly used for weight loss over the last four to five years00:04:04: Dr. Brackney notes these medications are also being used for patients with cardiovascular conditions and kidney disease, showing decreased complications00:04:28: Dr. Wolfe mentions recent approval for people who are overweight with sleep apnea, predicting more indications will emerge00:04:42: Cost identified as one of the biggest barriers to these medications becoming more popular00:05:01: Dr. Brackney reports that semaglutide and tirzepatide show potential for over 10% weight loss, while liraglutide shows 5-15% total weight loss00:05:49: Discussion of side effects, with nausea and constipation being the most common, though they are treatable and many people adjust over time00:06:09: Dr. Wolfe asks about common brand names versus generic names for listener clarity00:06:25: Dr. Brackney lists brand names including Ozempic, Wegovy, Rybelsus (semaglutide), Trulicity (dulaglutide), Victoza and Saxenda (liraglutide), and Mounjaro (tirzepatide)00:07:02: Discussion of compounded medications versus manufacturer medications, with Dr. Brackney noting compounded versions are not FDA-regulated and therefore not considered as safe00:07:55: Dr. Wolfe transitions to discussing pregnancy and the phenomenon of "Ozempic babies"00:08:51: Dr. Brackney explains that obesity reduces fertility, with obese women having three times higher risk of infertility and 40% higher miscarriage rates00:10:28: Discussion of how GLP-1 medications may interfere with contraceptive distribution in the body due to slowed gastric emptying00:11:04: Dr. Wolfe summarizes that better overall health, weight loss, and potential contraceptive interference all contribute to "Ozempic babies"00:11:27: Dr. Brackney recommends discontinuing GLP-1 medications at least one to two months before trying to get pregnant, noting limited data on ideal timing00:12:38: Discussion of the lack of...

⁠Assessoria esportiva online e cursos⁠⁠⁠⁠⁠⁠⁠ | ⁠⁠⁠⁠⁠⁠⁠E-book "Dieta Inteligente - Para Perder Gordura e Ganhar Massa Muscular" – só R$ 39,90⁠⁠⁠⁠⁠⁠⁠ | ⁠⁠⁠⁠⁠⁠⁠Curso de Treino – Monte seu próprio treino ainda hoje⁠⁠⁠⁠⁠⁠⁠ | ⁠⁠⁠⁠⁠⁠⁠Curso de Emagrecimento – Como emagrecer e nunca mais engordar ⁠⁠⁠⁠⁠⁠⁠| ⁠⁠⁠⁠⁠⁠⁠Curso Sobre Esteroides Anabolizantes – Não use esteroides antes de fazer este curso ⁠⁠⁠⁠⁠⁠⁠| ⁠⁠⁠⁠⁠⁠⁠Curso de Suplementação para Praticantes de Musculação⁠⁠⁠⁠⁠⁠⁠ | ⁠⁠⁠⁠⁠⁠⁠Grupo do Telegram com promoções⁠⁠⁠⁠⁠⁠⁠ | ⁠⁠⁠⁠⁠⁠⁠Instagram⁠⁠⁠⁠⁠⁠⁠ | ⁠⁠⁠⁠⁠⁠⁠Facebook⁠⁠⁠⁠⁠⁠⁠ | ⁠⁠⁠⁠⁠⁠⁠Growth⁠⁠⁠⁠⁠⁠⁠ | ⁠⁠⁠⁠⁠⁠⁠Oficialfarma⁠

Topics We Cover: 00:00 – New data from Harvard/Mass General may classify nearly 70% of adults as having obesity 03:00 – A new oral triple agonist shows record-setting absorption rates 07:00 – Fractal Health's Revita procedure: weight maintenance after stopping GLP-1s 12:00 – Zepbound vial prices drop (full breakdown by dose) 16:00 – Dave's personal experience switching off Mounjaro and intense hunger return 22:00 – Novo Nordisk's EVOKE/EVOKE+ Alzheimer's trial: what the data really means 29:00 – Why GLP-1 neurological research is just getting started 33:00 – Updates on access, partners, and major news coming soon for Medicare patients If you're on Wegovy, Mounjaro, Zepbound, Saxenda, Trulicity, or compounded versions, this episode gives you the insight and context you need to have more competent and confident conversations with your doctor. Bullet Point Summary of the Podcast Episode New Obesity Measurement Data (Harvard/Mass General Study) Harvard and Mass General propose adding waist circumference to BMI to better diagnose obesity. Traditional BMI misses key factors like muscle mass and body composition. Using the updated measure, Americans classified as obese jumps from ~43% to almost 69%. This means 7 out of 10 U.S. adults would now qualify as having the disease of obesity. Dave notes this validates many people who “feel” metabolically unwell despite a “normal” BMI. Reinforces his claim that “most people should be talking to their doctors about GLP-1s.” New Oral Triple Agonist (Ascletis – ASC41/ASC? Molecule) From Ascletis (A-S-C-L-E-T-I-S), developing an oral triple agonist targeting: GLP-1 GIP Glucagon Similar in mechanism to retatrutide, expected around 2027. Preclinical (animal) data show stunning results: Oral bioavailability of 4.2% 9× higher than tirzepatide 30× higher than oral semaglutide 6× higher than oral retatrutide 57× greater drug exposure than oral retatrutide Half-life ~56 hours Stronger receptor activation than retatrutide in vitro Suggests potential for the first powerful oral triple agonist—worth watching. ️ 3. Discussion of the Gray Market / TikTok Experience Dave briefly recounts losing his TikTok account and landing in an algorithm filled with teenagers promoting gray-market “retatrutide.” Expresses concern over unregulated peptide sales, especially to minors. Fractal Health's New Data – Weight Maintenance After Stopping GLP-1s New results from the Reveal One study (Fractal Health). Participants: lost 24% of body weight on GLP-1s → stopped injections → got one Revita procedure. At 6 months post-GLP-1 discontinuation: Weight changed only 1.5% (vs. ~10% regain in typical off-drug trials) HbA1c barely shifted Safety profile clean Suggests possible long-term weight maintenance without injections through gut mucosal re-lining. Dave describes his own recent attempt to switch drugs and significant hunger return. Food Noise & Biologic Hunger Dave discusses how stopping Mounjaro caused terrifying, primal hunger. Describes the distinction between: Food noise (brain-based thoughts) Hunger signals (biological/animalistic) Reinforces why many patients cannot maintain weight loss without support. Zepbound (Tirzepatide) Cash-Pay Price Reductions Eli Lilly drops cash-pay vial pricing: 2.5 mg: $349 → $299 5 mg: $499 → $399 7.5–15 mg: $499 → $449 Community feedback (informal poll): Most say still too high to leave compounded versions. Many would switch to branded if price hit $200–$300. Dave notes the Most Favored Nations agreement will push GLP-1 prices toward $250/month within 24 months. Alzheimer's Study (Novo Nordisk – EVOKE & EVOKE+) Oral semaglutide (Rybelsus, 14 mg) did not slow Alzheimer's clinical progression. Biomarkers improved but daily function and cognitive decline did not improve vs placebo. Important context: Oral Rybelsus is a weak form of semaglutide; stronger versions (like Wegovy 2.4 mg or upcoming high-dose oral Wegovy) not tested. Weight loss is not desirable in Alzheimer's patients, influencing drug selection. Dave emphasizes: This was a nearly $700M trial and an act of scientific courage. This is NOT the end of GLP-1 Alzheimer's research. Future molecules may target neurological pathways without suppressing appetite. Mentions Lilly's brenipatide, a GIP receptor agonist being developed for: Addiction Opioid dependency Possibly asthma ️ 8. Access, Cost, and Patient Empowerment Highlights Shed as a partner offering telehealth GLP-1 access. Notes many patients hide GLP-1 use from their primary care doctors. Reinforces OTP's mission: better, more honest conversations with clinicians. Shapa (Numberless Scale) & Dave's Personal Update Dave explains how the Shapa numberless scale helped him stay engaged during weight fluctuations. Finds stepping on “zones” (green/gray/blue) less emotionally damaging than numbers. Closing Notes Promises upcoming Eli Lilly savings card update. Encourages subscribing, liking, and enabling notifications for algorithm visibility. Thanks OTP community for amplifying patient-centric obesity medicine news. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, meet in person at the Diabetes Technology Meeting (DTM) in San Francisco to discuss the latest clinical and regulatory advances surrounding semaglutide. Key Episode Timestamps 00:00:01 Introduction 00:00:42 Oral semaglutide's FDA approval 00:02:02 The SOUL trial and Rybelsus's cardiovascular indication 00:03:35 Dosing for Rybelsus 00:06:18 The SELECT trial 00:08:29 Can GLP-1s be cardiovascular treatments? 00:14:08 Outro

Leyla Muedin, a registered dietitian nutritionist, discusses the gastrointestinal (GI) side effects commonly experienced by patients using GLP-1 medications such as Ozempic and Rybelsus. Leyla introduces a nutraceutical called Digexin, created by N-X-T-U-S-A, which has shown promise in mitigating these side effects and improving overall well-being. The episode highlights the need for patients to prioritize animal protein intake and incorporate strength training to maintain muscle mass, especially when taking GLP-1 medications. Leyla emphasizes the importance of developing healthy habits and lifestyle changes to sustain weight loss after discontinuing these drugs.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into some of the most significant shifts occurring in these industries, touching on strategic restructuring, regulatory milestones, and groundbreaking scientific advancements that are shaping the future of drug development and patient care.Let's begin with a major corporate shakeup at Novo Nordisk. The company has announced a significant leadership transition as former CEO Lars Rebien Sorensen is set to become the new chairman of the board. This change follows the resignation of seven board members and indicates a strategic realignment within the company. The Novo Foundation's involvement suggests a deeper strategic shift, potentially aligning with new organizational objectives and innovations. Such moves are pivotal as they could influence Novo Nordisk's market position and future product development.Turning to scientific breakthroughs, Merck's collaboration with Kelun-Biotech has yielded promising results with their Trop2 antibody-drug conjugate, sacituzumab-tmt. This ADC has shown success in two Phase 3 trials targeting lung and breast cancers, underscoring the therapeutic potential of ADCs in oncology. By selectively targeting cancer cells while minimizing damage to healthy tissues, ADCs could significantly improve patient outcomes and represent a powerful modality in cancer treatment.In regulatory affairs, Kenvue is challenging the FDA over proposed safety warnings for Tylenol linked to autism during pregnancy. This dispute highlights the ongoing debates surrounding drug safety and regulatory oversight. The outcome could have significant implications for labeling practices and consumer trust in over-the-counter medications. Meanwhile, Summit Therapeutics plans to file for FDA approval of ivonescimab, highlighting ongoing innovation in drug development pipelines. Similarly, Novo Nordisk's semaglutide pill Rybelsus has received FDA expansion approval to reduce major adverse cardiovascular events. This sets a new benchmark for oral metabolism drugs by demonstrating their potential beyond glycemic control to positively impact cardiovascular health.As we explore industry trends, there's growing interest in direct-to-consumer drug sales. While this approach offers patients access to medications at reduced costs, it raises concerns about privacy and the quality of care without traditional healthcare provider interactions. Additionally, a notable decline in pharmaceutical TV ad spending by 19% in Q3 suggests a shift towards digital engagement strategies. Amidst these narratives, the Biotechnology Innovation Organization (BIO) has launched an awareness campaign to combat misinformation about vaccines. This effort underscores the importance of immunizations in public health and aims to reinforce trust amid rising disinformation.In another scientific advancement, GSK has released positive Phase 3 data for Spero Therapeutics' oral antibiotic candidate. The oral formulation's efficacy comparable to intravenous options could lead to broader use and improved patient adherence—critical advancements as antibiotic resistance remains a global health challenge.Investment activities reflect strategic shifts within the industry as well. Curewell Capital's investment in Wilmington PharmaTech aims to enhance U.S. active pharmaceutical ingredient production capacity—a crucial step given recent global supply chain disruptions. Similarly, India's ACG is making a $200 million investment in its first U.S. empty-capsule production facility, highlighting the strategic importance of manufacturing capabilities on American soil.Galapagos' decision to wind down its cell therapy unit marks a significant strategic pivot from its previous focus on this modality. This shift reflects broader industry trends where companies reassess priorSupport the show

Hoy quiero hablarte de dos medicamentos que se han vuelto cada vez más populares: Mounjaro y Rybelsus. Probablemente has escuchado que ayudan a bajar de peso, que son ‘la nueva revolución', o incluso que reemplazarán a Ozempic… pero, ¿qué hay detrás de todo esto? En este episodio te voy a explicar cómo funcionan, en qué se parecen y en qué se diferencian, y lo más importante: qué papel realmente tienen dentro de un cambio de hábitos saludables. Canal de Youtube Visita nuestra página web:  Hábitos Inteligentes ¡Síguenos en instagram!  Agenda tu cita por WhastApp     

Join Drs. Neil Skolnik and Sara Wettergreen as they answer one of the most common questions people living with diabetes have: “What diabetes medication is best for me?”   In this episode, they'll explore how choosing the right medication depends on your individual health, lifestyle, and goals. Discover practical tips to better help you work with your care team to make informed decisions and find the best treatment plan for you.   Presented by: Neil Skolnik, MD, Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health, Abington, PA Sara Wettergreen, PharmD, BCACP, BC-ADM, Assistant Professor, Department of Clinical Pharmacy, University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences; and Ambulatory Care Clinical Pharmacist, UCHealth Lone Tree Primary Care, Aurora, CO Do you have questions or comments you'd like to share with Neil and Sara? Leave a message at (703) 755-7288. Thank you for listening, and don't forget to “follow” Diabetes Day by Day!   Diabetes Medications: Biguanides Brand: Glucophage, Fortamet, Glumetza Generic: Metformin, Metformin XR Sulfonylureas (Second Generation) Brand: Glucotrol, Amaryl, Diaβeta, Glynase Generic: Glipizide, Glipizide XL, Glimepiride, Glyburide Thiazolidinediones (TZDs) Brand: Actos, Avandia Generic: Pioglitazone, Rosiglitazone (no longer available) DPP-4 Inhibitors Brand: Januvia, Onglyza, Tradjenta, Nesina Generic: Sitagliptin, Saxagliptin, Linagliptin, Alogliptin SGLT2 Inhibitors Brand: Invokana, Farxiga, Jardiance, Steglatro, Brenzavvy Generic: Canagliflozin, Dapagliflozin, Empagliflozin, Ertugliflozin, Bexagliflozin GLP-1 Receptor Agonists Brand: Victoza, Trulicity, Ozempic, Rybelsus, Mounjaro (dual GIP/GLP-1) Generic: Liraglutide, Dulaglutide, Semaglutide, Tirzepatide Insulins (selected examples) Brand: Humalog, NovoLog, Apidra, Lantus, Basaglar, Levemir, Tresiba, Humulin N, Novolin N, Humulin R, Novolin R Generic: Insulin lispro, Insulin aspart, Insulin glulisine, Insulin glargine, Insulin detemir, Insulin degludec, NPH insulin, Regular insulin

Écoutez l'essentiel de La commission du 9 septembre 2025: Expulsé de la CAQ, le député Pierre Dufour pourrait-il faire le saut avec le PLQ? «Je vais regarder toutes les options»; Ozempic, Rybelsus et Wegovy`«Ces médicaments n’auraient jamais dû devenir un phénomène de société»; Plafond d'embauche en éducation: «Des enfants paieront les frais d'une idiotie bureaucratique»; Des requins blancs dans le golfe du St-Laurent: «Il y en a de plus en plus». Voir https://www.cogecomedia.com/vie-privee pour notre politique de vie privée

Companies are spending big bucks advertising weight-loss drugs like Rybelsus, seeing huge potential in capitalizing on the popularity of Ozempic. But in Canada, so-called "reminder ads" can give only the name of the medication, not what it's for, telling people to ask their doctor for details. Ad man Terry O'Reilly says it can result in bad ads that turn people off, and pharmaceutical policy expert Barbara Mintzes says reminder ads can lead to overtreatment and high costs, doing more harm than good.

Those injection-free sublingual GLP-1 drops for individualized microdosing—do they actually work? Options for treating stubborn neuropathy; Her new doctor said, “Vitamins are hogwash”—so she fired him; There is hope for tinnitus—via diet and lifestyle; I'm taking German classes, and a new study suggests it'll help me ward off cognitive decline. 

Écoutez le meilleur de La commission du 13 août 2025: Québec injecte un demi-milliard de dollars pour acquérir une participation dans le fabricant québécois d'énergie verte Innergex. Défaite dans Arthabaska, remontée de l'intérêt envers le projet souverainiste chez les jeunes, loi 21 et stratégie de reconstruction du Parti libéral du Québec: le nouveau chef du PLQ, Pablo Rodriguez, fait le point sur plusieurs dossiers à La commission. Avez-vous changé votre façon de faire votre épicerie? Compte tenu de la popularité grandissante des magasins de grande surface, comme Super C, Maxi et Costco, la situation de Metro, qui confirme un bénéfice net et des ventes en hausse pour le troisième trimestre, est assez étonnante. Connaissez-vous quelqu’un qui prend Ozempic? Que ce soit Ozempic, Wegovy ou Rybelsus, les médicaments pour traiter le diabète ou la perte de poids connaissent un immense succès sur la planète. Certains saluent leurs vertus et d’autres les conspuent. On vous propose un grand tour de piste sur les effets secondaires de ces médicaments miracles.Voir https://www.cogecomedia.com/vie-privee pour notre politique de vie privée

I am honored to reconnect with Dr. Tracy Gapin today. He is a board-certified urologist and men's health expert.  The current state of metabolic health in the United States and most Westernized countries has sparked a great interest in a GLP1 agonist, AKA Semaglutide Ozempic. I wanted to speak with a clinician who actively uses this medication. Dr. Gapin and I discuss what this drug class represents. (These are synthetic peptides.) We speak about Semaglutide, Ozempic, Wegovy, and oral Rybelsus. We get into current research, side effects, who should not take these medications, the mechanisms of action specific to the pancreas and beta cells, reductions, gastric emptying, and the upregulation of satiety. We discuss changes in the brain regarding leptin and how these drugs work. We also talk about weight loss resistance, and I answer questions from listeners.  From my perspective, it all comes back to basics. I believe that if we are to prescribe these medications, we must help our patients understand how lifestyle impacts weight-loss resistance and metabolic health. I loved that Dr. Tracy spent some time talking about the specific ways he works with his patients, even before prescribing medications. He also explains how important he feels this drug has been for his patients. I approached today's conversation with an open mind, and I hope you will do the same. IN THIS EPISODE YOU WILL LEARN: GLP1 agonists, and how they help Dr. Tracy motivate his patients to lose weight What are GLP1 agonists, and how do they work? Physical benefits of GLP1 agonists Who is Semaglutide not appropriate for? Common side-effects of GLP1 agonists How those who fail to implement lifestyle changes when they stop using Semaglutide may regain all the weight they lost Hydration while using Semaglutide Protein intake when taking Semaglutide How to follow the metrics that matter Factors that could hinder successful weight loss What Dr. Tracy does to ensure his patients do not regain the weight they lost after they stop using Semaglutide Listener questions: Why is a diabetic drug being used for non-diabetics? Does this drug target muscle versus fat in terms of weight loss? For how long do most patients take it? Are there unique characteristics in perimenopausal and menopausal women that must be accounted for differently? Bio: Dr. Tracy Gapin is a board-certified urologist and a world-renowned expert in men's health and performance, as well as the founder of the Gapin Institute, the global leader in High-Performance Health.  He has over 20 years of experience focused on men's health optimization, human performance, and longevity, providing executives & entrepreneurs a personalized path to fulfill their highest potential. He's been featured in Entrepreneur, Dave Asprey's Biohacking Conference, and as a TEDx speaker. Connect with Cynthia Thurlow Follow on⁠ Twitter⁠,⁠ Instagram⁠ &⁠ LinkedIn⁠ Check out Cynthia's⁠ website⁠ Connect with Tracy Gapin On his⁠ website⁠ ⁠Gapin Institute⁠

Cet épisode est une présentation de Eros et Compagnie Code promo RAIS15 pour 15% de rabais⁠⁠⁠⁠⁠⁠https://www.erosetcompagnie.com/?code=rais15⁠⁠⁠⁠⁠⁠///ON A UN NOUVEL AMI YOUPPI YOUPPI!Épisode classique en mode trio cette semaine avec Julien Bernatchez, Murphy Cooper et Mathieu Niquette.Comme d'habitude, on dit bien de la sauce en intro: Murphy remercie Murphy, Niquette se rebaptise King Cringe, on reparle des sondes de Julien.On revient sur la domination du Des si et des rais verse dans le domaine de la publicité alors que Maxime, Linda et Niquette sont en grosse rotations dans les annonces de la télé québécoise. Et on en profite bien sûr pour taquiner Maxime sur son étrange et cryptique pub de Rybelsus. Murphy en profite pour annoncer qu'il joint lui aussi l'écurie de LOL LOL LOL, donc on le verra peut-être lui aussi prochainement au petit écran!Ensuite, dans les chroniques, Julien nous propose des diss-track à propos des autres podcasts et ça brasse en tabarouette! Puis Niquette nous révèle un pan de l'algorithme un peu brisé de la page Instagram de Des si et des rais!Et dans le segment Eros qui est pour le moins mémorable, Julien nous construit un ami qui pourra rester avec nous pour encore un bon moment!Des si et des rais: Quand personne ne veut jouer avec nous, on s'invente de nouveaux amis!Avec: Julien Bernatchez, Murphy Cooper et Mathieu NiquetteCaptation / Montage / Réalisation : Jonathan BarbeDate d'enregistrement: 12 avril 2025Date de diffusion: 15 mai 2025///Abonnez-vous à nos réseaux sociaux via le ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠LinkTree⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠YouTube⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Patreon⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Facebook⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Discord⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠TikTok⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Instagram⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠SpeakPipe

Semaglutide has become the weight management sensation of the decade, but what's the science behind the hype? In this episode, I break down how these GLP-1 agonists really work, why 85% of patients regain weight after stopping, and why I use them as just one tool in my comprehensive approach to metabolic health. From side effects to proper patient selection, get the unfiltered medical perspective you need before considering these medications. Episode Highlights: The meteoric rise of Ozempic, Wegovy and Rybelsus that's causing nationwide shortages How semaglutide actually works in your brain and digestive system to reduce appetite Why patients regain weight after stopping and the importance of lifestyle integration Real talk about side effects - from common digestive issues to rarer complications The critical shift needed in how medicine approaches obesity treatment Important differences between FDA-approved formulations and compounded alternatives My professional recommendations for patient selection and monitoring protocols How H.E.R. University supports comprehensive metabolic health beyond medication Episode Resources: Dr. Shawn Tassone's Practice | https://www.drshawntassone.com Dr. Shawn Tassone's Book | The Hormone Balance Bible Dr. Shawn Tassone's Integrative Hormonal Mapping System | Hormone Archetype Quiz Thank you to our sponsor, Endurance Products Company! After over 25 years of practicing medicine, I'll be the first to tell you that not all supplements are created equal. But when I discovered Dihydroberberine SR, by Endurance Products Company, I was genuinely impressed.  It's highly bioavailable and outperforms standard berberine at significantly lower doses. You can explore their offerings at endur.com. Not only is the science solid, but I love that Endurance Products Company is a family-run American company that has cared about doing things right since 1978. I've started recommending Dihydroberberine to my patients who struggle with blood sugar management, and the results speak for themselves. So much so, that I personally take this supplement for helping to support healthy blood sugar levels, heart health, and tap into how my body uses fats for energy As a special offer for my audience, Endurance Products Company is providing a 10% discount on your order! Simply use the code DRT10 at checkout when you visit endur.com. Medical Disclaimer This podcast and website represent the opinions of Dr. Shawn Tassone and his guests. The content here should not be taken as medical advice and is for informational purposes only. Because each person is so unique, please consult your health care professional for any medical questions.

Subscriber-only episodeResources for the Community:___________________________________________________________________https://linktr.ee/theplussidezpodcast Ro - Telehealth for GLP1 weight management https://ro.co/weight-loss/?utm_source=plussidez&utm_medium=partnership&utm_campaign=comms_yt&utm_content=45497&utm_term=55______________________________________________________________________Streamed live on Mar 26, 2025261 views • Streamed live on Mar 26, 2025Unlike traditional media, our live sessions offer raw, real-time discussions on obesity treatments. The community can engage directly in the comments, share their perspectives, and connect with experts and fellow patients. It's a space for honest dialogue, advocacy, and breaking the stigma around obesity, all while staying informed about the latest breakthroughs and understanding Mounjaro, Zepbound, Wegovy, Ozempic, Rybelsus, Saxenda, and Victoza and all the newest GLP1s.______________________________________________________________________⭐️Mounjaro Stanley⭐️griffintumblerco.Etsy.comUse code PODCAST10 for $ OFF______________________________________________________________________Join this channel to get access to perks:   / @theplussidez______________________________________________________________________#Mounjaro #MounjaroJourney #Ozempic #Semaglutide #tirzepatide  #GLP1 #Obesity #zepbound #wegovy  Kim Carlos, Executive Producer TikTok https://www.tiktok.com/@dmfkim?is_from_webapp=1&sender_device=pc Instagram https://www.instagram.com/dmfkimonmounjaro?igsh=aDF6dnlmbHBoYmJn&utm_source=qr Kat Carter, Associate Producer TikTok https://www.tiktok.com/@katcarter7?is_from_webapp=1&sender_device=pc Instagram https://www.instagram.com/mrskatcarter?utm_source=ig_web_button_share_sheet&igsh=ZDNlZDc0MzIxNw==

Subscriber-only episodeResources for the Community:___________________________________________________________________https://linktr.ee/theplussidezpodcast Ro - Telehealth for GLP1 weight management https://ro.co/weight-loss/?utm_source=plussidez&utm_medium=partnership&utm_campaign=comms_yt&utm_content=45497&utm_term=55Sign The Petition for Avoidable Access to GLP-1s https://glp1collective.org/ ______________________________________________________________________We discuss Wegovy, Ozempic, Mounjaro, Zepbound, Rybelsus, Saxenda, and Victoza and the active ingredients Tirzepatide and Semaglutide. Unlike traditional media, our live sessions offer raw, real-time discussions on obesity treatments, where the community can engage directly in the comments, share their perspectives, and connect with experts and fellow patients. It's a space for honest dialogue, advocacy, and breaking the stigma around obesity, all while staying informed about the latest breakthroughs. Tonight, we are joined by @Downsidezed    / @thedownsized  ______________________________________________________________________⭐️Mounjaro Stanley⭐️griffintumblerco.Etsy.comUse code PODCAST10 for $ OFF_____________________________________________________________________Join this channel to get access to perks:   / @theplussidez______________________________________________________________________#Mounjaro #MounjaroJourney #Ozempic #Semaglutide #tirzepatide  #GLP1 #Obesity #zepbound #wegovy  Kim Carlos, Executive Producer TikTok https://www.tiktok.com/@dmfkim?is_from_webapp=1&sender_device=pc Instagram https://www.instagram.com/dmfkimonmounjaro?igsh=aDF6dnlmbHBoYmJn&utm_source=qr Kat Carter, Associate Producer TikTok https://www.tiktok.com/@katcarter7?is_from_webapp=1&sender_device=pc Instagram https://www.instagram.com/mrskatcarter?utm_source=ig_web_button_share_sheet&igsh=ZDNlZDc0MzIxNw==

Ozempic (semaglutida) es un medicamento para el control de la diabetes tipo 2 que se ha popularizado por sus efectos para bajar de peso. En este episodio explicaremos qué es la semaglutida, una clase de fármacos conocidos como agonistas de la hormona GLP-1, de la que se derivan medicamentos como Ozempic, Wegovy y Rybelsus. Hablaremos de sus beneficios, de sus efectos secundarios y de los retos en materia de salud pública relacionados con su consumo. Para este episodio entrevistamos a Carolina Solís Herrera, jefa de la División de Endocrinología en la Universidad de Texas en San Antonio, a Abril Campos Rivera, profesora investigadora del Institute for Obesity Research y la Escuela de Gobierno y Transformación Pública del Tec de Monterrey y a Paola Portillo Sánchez, médico internista y endocrinóloga de Tec Salud. Asimismo, recabamos los testimonios de tres usuarios de Ozempic. Si te interesa informarte más sobre este tema te invitamos a escuchar el Episodio 74: Fármacos para bajar de peso, ¿cuándo sí? También puedes leer: Fármacos como Ozempic para bajar de peso, ¿cuándo sí? Los medicamentos para la obesidad no son soluciones mágicas Encuentra más información en: TecScience.tec.mx La plataforma de divulgación del Tec de Monterrey. Y para que siempre estés al día con las últimas tendencias en investigación, suscríbete a nuestro newsletter.

On this episode of Fat Science, Dr. Emily Cooper, Andrea Taylor and Mark Wright delve deeper into the topic of compounded metabolic drugs. Dr. Cooper addresses criticisms from listeners about the previous discussion and provides insights into the economic reasons driving people towards compounded drugs. She also dissects the ethics and economics of the diet industry transforming into a subscription medicine model and the role of insurance in accessibility to metabolic treatments.Key Takeaways:Compounded drugs often act as a misleading alternative to brand medications, lacking FDA approval and potentially jeopardizing health outcomes.Employers significantly influence weight-related treatment coverage, and advocacy for coverage changes can be a crucial step towards accessible medications.Insurance restrictions and economic barriers force many to explore compounded drugs despite potential risks.The rise of online subscription models parallels the diet industry's modus operandi of exploiting vulnerable demographics for profit.Greater transparency and regulation within the pharmaceutical and insurance sectors are needed to ensure safe and equitable access to treatments.Personal Stories & Practical Advice:Andrea reflects on her decision to prioritize health despite the significant cost by sourcing medications through Canada rather than risking compounded drugs.Discussions emphasize the importance of a comprehensive and guided medical approach, advocating for patient education and active engagement with healthcare providers.Important Update: Changes in GLP-1 Medication Availability and Compounding RegulationsThis episode was recorded before recent regulatory developments regarding GLP-1 medications. As of our current information:The FDA has determined that shortages have been resolved for all formulations of tirzepatide (marketed as Mounjaro and Zepbound) and semaglutide (marketed as Rybelsus, Ozempic, and Wegovy). Consequently, compounding these medications is no longer legally permitted under FDA regulations.Additionally, Novo Nordisk has expanded its patient assistance program by implementing enhanced coupon discounts across all Wegovy dosage strengths to improve affordability and access to match Lilly's efforts for Mounjaro and Zepbound access.Please note that regulatory policies and manufacturer programs regarding these medications continue to evolve. For the most up-to-date information, we recommend consulting current FDA announcements and manufacturer websites.Resources:Connect with Dr. Emily Cooper on LinkedIn.Connect with Mark Wright on LinkedIn.Connect with Andrea Taylor on Instagram.Fat Science is a podcast on a mission to explain where our fat really comes from and why it won't go and stay away. We are committed to creating a world where people are empowered with accurate information about metabolism and recognize that fat isn't a failure. This podcast is for informational purposes only and is not intended to replace professional medical advice.If you have a question for Dr. Cooper, a show idea, feedback, or just want to connect, email us at info@diabesityinstitute.org.Fat Science is supported by the non-profit Diabesity Institute which is on a mission to increase access to effective, science-based medical care for those suffering from or at risk for diabesity. https://diabesityresearchfoundation.org/

It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: New drug is looked at for T1D prevention, a new stem cell method is tested for beta cell transplanation without immunosuppresion drugs, the FDA okays the first fast-acting biosimilar insulin, Lilly lowers price of Zepbound, and more! Find out more about Moms' Night Out  Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom  Edgepark Medical Supplies Check out VIVI Cap to protect your insulin from extreme temperatures Learn more about AG1 from Athletic Greens  Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.com Episode transcription with links:   Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. XX New research in type 1 diabetes prevention launches. Nektar Therapeutics and TrialNet will evaluate a drug currently used for exzema for patients with new onset stage 3 type 1 diabetes The drug is RezPeg – that's a shortened version of the name (rezpegaldesleukin)   This will be a study of about 70 adults and children and will launch this year. The new study will use a mixed meal tolerance test (MMTT) to measure the efficacy of rezpegaldesleukin or placebo for preserving C-peptide area under the curve over a 12-month duration comprised of a 6-month treatment period and a 6-month follow-up. Secondary objectives include pharmacokinetics, pharmacodynamics, and additional disease assessments including HbA1c levels and patient insulin requirements. Rezpegaldesleukin is being developed as a self-administered injection for a number of autoimmune and inflammatory diseases. https://www.prnewswire.com/news-releases/nektar-announces-clinical-trial-agreement-to-evaluate-rezpegaldesleukin-in-patients-with-new-onset-type-1-diabetes-mellitus-302383052.html XX NLS Pharmaceutics (NLSP) and Kadimastem announced successful completion of a pre-IND meeting with the FDA for iTOL-102, a potential diabetes treatment. iTOL-102 combines Kadimastem's IsletRx cells (stem cell-derived pancreatic islets) with iTolerance's immunomodulator iTOL-100, aiming to cure Type 1 Diabetes without requiring life-long immune suppression. The treatment was evaluated at the Diabetes Research Institute at the University of Miami School of Medicine, where it demonstrated functional insulin release and disease reversal in animal models. Based on FDA feedback, the companies are updating plans for safety toxicology studies and First-in-Human clinical trials. IsletRx is a clinical-grade product comprising human pancreatic islet-like cells capable of secreting insulin, offering a scalable source of insulin-producing cells to address donor islet shortages. The technology can detect glucose levels and produce required amounts of insulin and glucagon.   XX FDA has signed off on a rapid-acting insulin biosimilar for the first time. The agency has given a thumbs up to Sanofi's Merilog (insulin-aspart-szjj) as the first biosimilar to Novo Nordisk's NovoLog for patients with diabetes. Merilog will be provided by prefilled pen in a 3 mL dose or in a multiple-dose 10 mL vial. It is for adults and pediatric patients age 6 and older.     NovoLog and Novo Nordisk's other rapid-acting insulin follow-on Fiasp are among the drugs subject to government price negotiations under the Inflation Reduction Act. The new prices will be enacted at the start of next year. In July 2021, the FDA approved Biocon and Viatris' Semglee (insulin glargine-yfgn) as the first biosimilar to Lantus. Five months later, the U.S. regulator endorsed Eli Lilly's version of the drug, called Rezvoglar (insulin glargine-aglr). https://www.fiercepharma.com/pharma/fda-signs-sanofis-biosimilar-first-novo-nordisks-rapid-acting-novolog XX Eli Lilly said Tuesday that it will offer more doses of its obesity drug Zepbound in vials and lower the prices of the doses it already sells, as the pharma giant seeks to draw patients away from cheap, compounded copies of weight loss medications. The company launched 7.5 mg and 10 mg vials of tirzepatide, sold under the brand name Zepbound, which typically cost $599 and $699, respectively. However, they are now available for $499 per month for patients paying without insurance. This applies to the first fill and all refills that are delivered every 45 days. Additionally, the company lowered the prices of the 2.5 mg and 5 mg vials to $349 and $499 per month, respectively. The company, which has seen a significant boost in profits from Zepbound and Mounjaro – essentially the same drug with different FDA-approved uses – announced that the new vials and pricing are exclusively available through the company's self-pay pharmacy, LillyDirect Self Pay Pharmacy Solutions. https://www.bloomberg.com/news/articles/2025-02-25/zepbound-cost-for-vials-cut-to-battle-cheaper-copycats XX Medicare spending on 10 diabetes drugs, including popular GLP-1s, more than quadrupled over a five-year period and could reach $102 billion next year, an analysis by Health and Human Services' inspector general found. The findings also come as the Trump administration weighs the fate of a Biden administration proposal that would require Medicare and Medicaid to cover GLP-1s for weight loss. The biggest spikes in usage were for Rybelsus, Novo Nordisk's once-daily GLP-1 tablet, and for the company's weekly injectable Ozempic, whose spending about doubled every year under review. https://www.axios.com/2025/02/25/medicare-spending-surge-diabetes-drugs XX Tandem Diabetes Care has secured a new FDA clearance for its insulin dose-calculating algorithm, opening up Control IQ for use in adults with Type 2 diabetes. The expanded label was based on data from a pivotal, randomized trial of more than 300 people with Type 2 diabetes, comparing its use to manual multiple daily injections. Tandem said it plans to present the study's results at the annual Advanced Technologies & Treatments for Diabetes meeting scheduled for next month in Amsterdam. https://www.fiercebiotech.com/medtech/tandem-diabetes-care-insulin-dosing-algorithm-nets-fda-clearance-type-2-diabetes XX Drugs approved for diabetes and obesity might be useful for the treatment of cognitive and mental health disorders, according to a new paper published in Nature Mental Health.   The study reviewed and integrated data from both preclinical and clinical studies to gather evidence on the possible effects of these drugs GLP1s and semaglutide  in conditions such as dementia, substance use disorders, psychotic disorders, mood and anxiety disorders, and eating disorders.     The study found promising but still preliminary evidence that GLP-1RAs could be beneficial over a range of cognitive and mental health disorders. These drugs have shown potential in improving cognition, reducing addictive behavior, and alleviating depression and anxiety. More data from robustly designed studies (i.e., randomized controlled trials) are needed to better understand GLP-1RAs' prospective efficacy and safety profile, especially with long-term use. https://medicalxpress.com/news/2025-02-diabetes-drugs-mental-health-treatment.html XX The FDA  issued draft guidance that includes recommendations to support the development and marketing of safe and effective AI-enabled The guidance, if finalized, would be the first guidance to provide comprehensive recommendations for AI-enabled devices throughout the total product lifecycle, providing developers with an accessible set of considerations that tie together design, development, maintenance, and documentation recommendations to help ensure the safety and effectiveness of AI-enabled devices. FDA is requesting public comment on this draft guidance by April 7. The agency also released draft guidance for the use of AI to support regulatory decision-making for drug and biological products. https://www.mddionline.com/artificial-intelligence/fda-issues-draft-guidance-for-ai-enabled-devices-seeks-public-feedback XX Congrats to Mila Clarke who some of you may know better as Hangry Woman on social. She has developed a great app called Glucose Guide and the Nutrition Assistant portion of that app went live this week. Glucose Guide is a web and mobile app that offers diabetes meal tracking, coaching, resources, recipes and community to those looking for help managing diabetes. MEAL AND BLOOD SUGAR TRACKING FEATURES.

In this enlightening episode of Healthy AF, Amy dives into the comprehensive world of GLP-1 RA drugs and their impact on weight loss. Whether you're contemplating starting a GLP-1 RA regimen or already on one and seeking more insight, this episode is packed with all the good information you need. Amy covers everything from the basics of GLP-1 RA drugs to the latest updates and data up to 2024. Discover practical advice on what additional health measures you can take while on these drugs to mitigate adverse effects and sustain weight loss. Tune in to arm yourself with knowledge and make informed decisions about your health journey with GLP-1 RA drugs. Trying to get healthy and stay healthy is f-ing hard! Everybody struggles with some aspect of it, no matter what they look like or what they tell you. There is no magic formula - a healthy lifestyle is a choice we need to make daily. Join Amy as she supports, informs, and entertains you on your journey toward health.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

GLP-1 agonists have taken the pharma world by storm, and Novo Nordisk has been at the forefront of it all with its blockbuster drug semaglutide, which it sells as Ozempic, Wegovy and Rybelsus. Semaglutide and other GLP-1s have gained widespread popularity as treatments for Type 2 diabetes and obesity, and it doesn’t stop there—they’re currently being tested in a wide variety of additional therapeutic areas and in new dosages and forms. In this week’s episode of “The Top Line,” Fierce’s James Waldron talked to Marcus Schindler, Novo’s chief scientific officer and executive VP of research and early development, about what’s next for GLP-1s and what else is top of mind at the Danish pharma. To learn more about the topics in this episode: Novo Nordisk hails ‘remarkable’ weight loss result for dual-acting oral drug in early trial Novo obesity prospect linked to ‘mild to moderate neuropsychiatric side effects’ in phase 2 Novo Nordisk axes once-monthly GLP-1/GIP agonist and MASH prospect Another day, another win for Novo in obesity, as early oral med appears to beat Wegovy See omnystudio.com/listener for privacy information.

Medications like Trulicity, Ozempic and Rybelsus help those with Type 2 diabetes manage their blood sugar levels. They're also being used for weight loss, and are believed to have other health benefits.

It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: World Diabetes Day roundup, existing drugs examined for T1D prevention, Blue Circle Health expands its novel T1D care model, Mounjaro studied further, Canada approves a new pumps system, and tragedy in the diabetes community.  Find out more about Moms' Night Out  Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom  Edgepark Medical Supplies Check out VIVI Cap to protect your insulin from extreme temperatures Learn more about AG1 from Athletic Greens  Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.com Episode transcription with links:   Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. XX Of course, World Diabetes Day was yesterday. November 14 marks the birthday of Sir Frederick Banting. who discovered insulin along with Charles Best in 1922. Lots of the tech companies are taking action.. I'm going to link up a great article highlighting what many of them are doing…. from Medtronics Blue Balloon challenge to Dexcom's Nick Jonas video and a lot more. https://www.drugdeliverybusiness.com/world-diabetes-day-2024/ XX A new triple combo therapy could restore insulin production in people with type 1 using existing medications. Levicure's triple-combo oral therapy is already considered very safe, because it involves two drugs approved by the U.S. Food and Drug Administration (FDA) and a well-known supplement. The therapy is a combination of: DPP4-inhibitors, a common type 2 diabetes medication Proton pump inhibitors (PPIs), a drug for severe acid reflux A proprietary version of gamma-aminobutyric acid (GABA), a supplement often used to treat anxiety Levicure says the combined effect can block beta cell destruction, suppress autoimmunity, and restore beta cell function. So far, Levicure's triple therapy has gone through only one retrospective chart review; it has not been put to the test in a randomized controlled trial https://www.diabetesdaily.com/blog/can-this-triple-combo-oral-therapy-restore-insulin-production-733261/   XX Blue Circle Health is expanding it's unique approach to type 1 care. Already active in Florida, Maine & Vermont, it will now be in Delaware and Ohio. Blue Circle Health is free and develops a personalized care plan for each participant, tailored to their unique needs, and offers comprehensive multidisciplinary support over a six-month period. It's paid for by the Helmsley Charitable Trust. The program is available to people 18 years of age and older that speak Spanish or English, regardless of insurance coverage or citizen status. We've got an upcoming podcast episode all about Blue Circle coming up soon. https://www.prnewswire.com/news-releases/blue-circle-health-expands-to-delaware-and-ohio-to-address-health-system-barriers-to-type-1-diabetes-care-and-education-302304170.html XX An international team of experts has created the world's first evidence-based guide for eating lower and low carb. The group says until now, people with type 1 diabetes and their healthcare providers have lacked comprehensive resources to help implement this approach safely and effectively. The guide provides essential information for dietitians and nutritionists and empowers them to work collaboratively with individuals and families who are interested in reducing carbohydrates. It's free and we've got the download link in the show notes. https://www.newswire.ca/news-releases/international-team-launches-first-guide-for-carbohydrate-reduction-in-type-1-diabetes-883729104.html XX A new pump system is available in Canada. mylife YpsoPump insulin pump and CamAPS FX hybrid closed-loop algorithm by Health Canada. mylife Loop consists of the mylife YpsoPump, a lightweight intuitive insulin pump, integrated with the CamAPS FX hybrid closed-loop, a mobile phone-based algorithm, and the Dexcom G6 Continuous Glucose Monitoring (CGM) System. Working together, these components provide an innovative, automated insulin delivery (AID) system designed to simplify insulin therapy and improve glycemic control for Canadians living with diabetes.   "The approval of the mylife YpsoPump and CamAPS FX marks an important milestone as we bring these advanced technologies to the Canadian market," said Sébastien Delarive, Chief Business Officer of Ypsomed Diabetes Care. "Although Ypsomed is relatively new in Canada, our established leadership in diabetes care throughout Europe provides a solid foundation for delivering innovative solutions to Canadians living with type 1 diabetes."   "We are excited to see both mylife YpsoPump and CamAPS FX approved," said Karina Schneider, General Manager at Ypsomed Canada. "This step brings us closer to offering an integrated solution that will help simplify diabetes management for Canadian patients, empowering them to take more control of their health." https://finance.yahoo.com/news/ypsomed-camdiab-receive-health-canada-205500840.html XX The FDA updates the labels for all GLP-1 receptor agonists with a warning about pulmonary aspiration during general anesthesia or deep sedation. The affected drugs are semaglutide (Ozempic, Rybelsus, Wegovy); liraglutide (Saxenda, Victoza); and the dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 tirzepatide (Mounjaro, Zepbound). the Medication Guide section of the label also has new additions. Patients are counseled to tell their healthcare provider if they are scheduled to have surgery or other procedures that use anesthesia or deep sleepiness (deep sedation). They are alerted that the GLP-1 RAs they are taking may cause serious side effects, including food or liquid getting into the lungs during surgery or other procedures that use anesthesia or deep sedation. Patients are advised to tell all their healthcare providers that they are taking a GLP-1 RA before they are scheduled to have surgery or other procedures. https://www.medscape.com/viewarticle/fda-updates-glp-1-label-pulmonary-aspiration-warning-2024a1000k84?form=fpf XX Following an impressive data drop this summer highlighting the potential for Eli Lilly's tirzepatide to stave off progression to Type 2 diabetes in prediabetic patients, the Indianapolis-based drugmaker is laying out full results from its longest completed study of the dual GIP/GLP-1 receptor agonist to date. In the three-year SURMOUNT-1 trial, tirzepatide curbed the risk of disease progression to Type 2 diabetes by 94% versus placebo in adult prediabetes patients who were obese or overweight, Lilly said in a release Wednesday. The number represents a pooled result from three tirzepatide doses (5 mg, 10 mg and 15 mg) studied in the trial.   Putting those results into perspective, one new case of diabetes could be prevented for every nine patients treated with tirzepatide, which is marketed in the U.S. as Mounjaro for Type 2 diabetes and as Zepbound for obesity, Lilly said. https://www.fiercepharma.com/pharma/lilly-unwraps-detailed-data-showing-tirzepatide-kept-nearly-99-pre-diabetic-patients XX Edgparke commeical? XX https://www.bloomberg.com/news/articles/2024-10-25/apple-secretly-tests-blood-sugar-app-in-sign-of-health-ambitions XX XX And finally, many of you have likely already heard but we had some incredibly tragic news in the diabetes community, especially for the Breakthrough T1D ride community. I'm going to read from the Breakthrough T1D website: The leadership, staff, and volunteers of Breakthrough T1D mourn the tragic, sudden loss of five T1D Champions on Friday, Nov. 1, 2024.  Jeff and Michelle Bauer, Josh and Tammy Stahl and Barry Sievers were all killed in a singe car crash. The group included two married couples and one single individual—all very close friends and veteran Breakthrough T1D Ride participants. Of this incredibly impactful group, I knew Michelle Bauer personally, I met her as Michelle Alswager – you may know her as Jesse's mom. Her son, Jesse died from complications of type 1 in 2010. And that year, mile 23 on the JDRF ride was created as a mile of silence in memory of Jesse.  Now all riders are asked to ride in silence for that mile not only in memory of Jesse, but all those lost to type 1 diabetes. Michelle wrote her book, Jesse Was Here and created a program that's part of Beyond Type 1 to this day, all to help other families going through grief. She called me a few years ago when she was thinking of writing her book and I'm so grateful for our conversations and that our conversations may have helped her get it out there into a world where it's so needed. But we need Michelle here to talk about grief. More about talking to Michelle about the book).   Please, write the book, ride the bike, do the ironman, follow your heart and your dreams.  All of these incredible people gone too soon. https://www.breakthrought1d.org/news-and-updates/breakthrough-t1d-mourns-tragic-sudden-loss-of-five-ride-champions/   Thanks for joining me..

We're seeing a LOT more medications like Ozempic in the emergency department nowadays. In fact, 12% of U.S. adults have used a GLP-1 drug! So, what do we need to know about these drugs? Dr. Megan Boysen Osborn, Professor of Emergency Medicine at the University of California Irvine, discusses these GLP-1 agonists with host Maiya Smith.

Vidcast:  https://www.instagram.com/p/DBuFOozsd4X/ Taking semaglutide, marketed as Ozempic, Rybelsus, and Wegovy, reduced the risk of developing Alzheimer's Disease by 40 up to 70 percent, compared with other medications.  This the finding of a large retrospective case study of over 1 million type 2 diabetics by Cleveland's Case Western University  and published in the Alzheimer's Association journal. The researchers compared the incidence of a first time diagnosis of Alzheimer's in those diabetics taking semaglutide versus those taking insulin or other diabetic medications.  Semaglutide reduced the risk of this dementia by 67% compared with insulin and even a more moderate 41% compared with other GLP-1 receptor agonists but not the newest tirazepatide.  This benefit was true for type 2 diabetics with or without a diagnosis of obesity. This observation, if confirmed with prospective randomized studies, could add Alzheimer's Disease prevention to the list of benefits for the GLP-1 receptor agonists which already include cardiovascular disease and stroke. https://alz-journals.onlinelibrary.wiley.com/doi/10.1002/alz.14313 #semaglutide #alzheimers #glp1ra #diabetes #obesity

In this episode of Hart2Heart with Dr. Mike Hart, Dr. Hart does a solo on GLP-1 agonists, especially Ozempic, and how they impact weight loss by reducing appetite and slowing gastric emptying. Originally designed for diabetes management, these drugs also help in lowering blood sugar levels. While many people have had success with weight loss, the host also discusses the challenges, such as side effects (nausea, gastrointestinal issues) and the potential return of cravings after stopping the medication. Dr. Hart stresses the importance of gradual dosing and mindful eating to sustain weight loss. Dr. Hart also touches on other GLP-1 drugs like Wegovy and oral forms like Rybelsus, comparing their effectiveness and applications. Show Notes: (0:00) Welcome back to the Hart2Heart Podcast with Dr. Mike Hart    (0:15) Dr. Hart is covering GLP-1 agonists and Ozempic (1:00) Understanding GLP-1 agonists (3:00) Different forms and dosages (10:00) Benefits and uses of GLP-1 agonists (11:30) Benefits beyond weight loss - cardiovascular health and neuroprotection (13:00) Common and serious side effects (17:03) How to avoid losing muscle mass (20:00) The deets on “Ozempic Face” (21:00) Mental state and cravings on Ozempic  (22:00) Managing cravings after stopping Ozempic (28:00) Cost considerations of GLP-1 agonists (29:30) Intro to Tirzepatide or Mounjaro  (31:30) Mechanisms and benefits of Tirzepatide (33:30) Clinical trials and side effects of Tirzepatide (36:00) Final thoughts and recommendations --- Dr. Mike Hart is a Cannabis Physician and Lifestyle Strategist. In April 2014, Dr. Hart became the first physician in London, Ontario to open a cannabis clinic. While Dr. Hart continues to treat patients at his clinic, his primary focus has shifted to correcting the medical cannabis educational gap that exists in the medical community.  Connect on social with Dr. Mike Hart: Social Links: Instagram: @drmikehart Twitter: @drmikehart Facebook: @drmikehart  

Amy's on a new Bravo lesbian tv show, Ryan's hair is old and brittle, baby shower etiquette, Riley- Ruler of Elves, Sabrina Carpenter, we dissect the Rybelsus commercial, Amy's new obsession is ‘Nobody Wants This', Ryan zooms with a couple in bed, Amy goes camping with her Dad, we chat fish from other planets, Ryan farts on a second date, Amy has an intimate experience at Jewel Lake, a listener PLT story about a nice viking wedding, Lil Donna is back with a European PLT story and we play Rupaul Song Or Not! Hosted on Acast. See acast.com/privacy for more information.

Nutritionist Leyla Muedin discusses the popular pharmaceutical semaglutides, including Ozempic, Wegovy, and Rybelsus. She explains their mechanisms of action, uses, and common side effects. Leyla also introduces Calocurb, a natural alternative made from hops, and explains how it can mimic the effects of semaglutides by stimulating the release of crucial digestive hormones. Throughout the episode, she emphasizes the importance of a balanced diet rich in fats and proteins for optimal health and weight management.

Companies are spending big bucks advertising weight-loss drugs like Ozempic and Rybelsus. This week, we're dropping an episode of Brian Goldman's White Coat, Black Art podcast into our feed.We thought you might find the topic interesting. In Canada, "reminder ads" can only give the medication's name, but they can't tell you what the drug is for. They just tell people to ask their doctor for more information. I join Dr. Goldman in this episode to talk about those ads.Are those ads good – or are they bad? Hosted on Acast. See acast.com/privacy for more information.

Companies are spending big bucks advertising weight-loss drugs like Rybelsus and Ozempic. But in Canada, "reminder ads" can give only the medication's name, not what it's for, telling people to ask their doctor for more. Special guest Terry O'Reilly, host of CBC's Under the Influence, says it can result in bad ads that turn people off, while pharmaceutical policy expert Barbara Mintzes says reminder ads can do more harm than good.

It's In the News! A look at the top diabetes stories and headlines happening now. Top stories this week: Dexcom CGM is worn in space, two over-the-counter CGMs are now available, a large new study looks at potential dietary causes of type 1, and researchers are looking at a gel version of GLP-1 medications. Find out more about Moms' Night Out  Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom  Edgepark Medical Supplies Check out VIVI Cap to protect your insulin from extreme temperatures Learn more about AG1 from Athletic Greens  Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.com Episode transcription with links:   Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. XX Astronauts on the Polaris-Dawn mission are wearing the Dexcom G6 CGM. Polaris Dawn launched this week with astronauts wearing the G6 to better understand the effects of spaceflight on human health. The crew intends to conduct research to advance human health on Earth and the understanding of health during long-duration spaceflights. “This health research-driven mission marks another first for Dexcom, with our industry-leading CGMs being worn by astronauts in outer space,” said Jake Leach, EVP and COO at Dexcom. “We are thrilled to play a role in building a future where people with diabetes are empowered to accomplish anything they set their minds to–including the possibility of exploring outer space–without being held back by their condition.” Over five days in space, the Polaris Dawn crew plans to conduct around 40 scientific experiments. That includes several aimed at better understanding the effects of spaceflight on glucose health. Labront, a platform assisting health researchers in collecting and analyzing physiological data, is collaborating with Dexcom. It plans to provide advanced analytics for the data collected by the crew.   According to a news release, the mission expects to explore how microgravity, fluid shifts, and blood flow restriction exercises impact glucose regulation. https://www.drugdeliverybusiness.com/dexcom-cgm-outer-space-polaris-dawn/ XX There are now two OTC CGMs.. Dexcom launched Stelo a few weeks ago and now Abbott says Lingo is for sale. They're both available on the companies' websites, cost about the same, but you can opt to buy only one Lingo where Stelo comes in pairs. Lingo is meant for people without diabetes – it's a health bio sensor. Abbott has another CGM called Libre Rio meant for people with type 2 who don't take insulin. Not a lot of details about what the real difference are here – likely just in the software – No word on when Rio will be available. https://www.cnbc.com/2024/09/05/-abbott-launches-its-first-over-the-counter-continuous-glucose-monitor-in-the-us.html XX Warning about flying with an insulin pump – And I want to be clear here because I'm sure you'll see some scary headlines. This is really about pressure emergencies in planes. For the study, researchers tested 26 insulin pumps in a hypobaric chamber programmed to mimic the atmospheric changes during a normal commercial airline flight. “The drop in cabin pressure during ascent may lead to a slight increase in insulin delivery as a result of the formation of air bubbles which displace excess insulin out of the cartridge,” Fan said in a meeting news release. “A slight reduction in insulin delivery is also possible during descent as the increasing air pressure dissolves the air bubbles, sucking insulin back into the pump.” People on insulin pumps could be in real trouble in the event of rapid decompression of the cabin at altitude, researchers said. In that case, the pumps could deliver an insulin overdose -- dropping blood sugar levels so much that there's a significant risk of hypoglycemia, results show. These researchers recommend disconnecting and reconnect at take off and landing, but that's not going to help if there is emergency rapid decompression. As always, be prepared with emergency glucagon and low snacks and supplies. https://www.healthday.com/health-news/diabetes/flying-could-upset-insulin-pump-function-for-type-1-diabetics XX Lilly moves forward with it's version of once weekly basal insulin. Clinical trials show it can help control both Type 1 and Type 2 diabetes as well as daily basal injections do. However, in those with type 1 diabetes, there was an increased risk for hypoglycemia.  This is the same issue with Novo Nordisk's Awiqli insulin – approved in Canada but not in the United States. https://www.upi.com/Health_News/2024/09/11/weekly-insulin-injections-effective-diabetes-weekly/8711726068680/ https://www.medscape.com/viewarticle/once-weekly-insulin-looks-good-t2d-risk-seen-t1d-2024a1000gh8 XX Eating what seems like really healthy foods could be associated with a higher risk of developing type 1 diabetes. New study shows that eating fruit, oats and rye in childhood is associated with a higher risk of developing type 1 diabetes (T1D). Eating berries, however, is linked to lower odds of developing the condition. What triggers the immune system's attack is unknown but is thought to involve a combination of a genetic predisposition and an environmental trigger such as a virus or foodstuff. T1D, the most common form of diabetes in children, is increasing worldwide. The number of cases worldwide is projected to double in just 20 years, from 8.4 million in 2021 to 17.4 million by 2040. Finland has the highest incidence of T1D globally, with 52.2 cases per 100,000 children under the age of 15 – more than five times higher than in the 1950s. 5,674 children (3,010 boys and 2,664 girls) with genetic susceptibility to T1D were followed from birth to the age of six. Food records completed by their parents repeatedly from the age of three months to 6 years provided information on the entire diet.   The 34 food groups covered the entire diet and, when they were all factored in, several foods were associated with a higher risk of developing T1D.   To the best of our knowledge, this is the first time a child's entire diet has been considered at the same time." The results show that the more fruit, oats or rye children ate, the more their risk of T1D increased. In contrast, eating strawberries, blueberries, lingonberries, raspberries, blackcurrants and other berries appeared to provide protection against T1D. The more berries a child ate, the less likely they were to develop T1D. Oats, bananas, fermented dairy products (such as yogurts) and wheat were associated with an increased risk of islet autoimmunity, whereas cruciferous vegetables, such as broccoli, cauliflower and cabbage, were associated with decreased risk. It is, however, too early to make any dietary recommendations. The researchers are quick to point out that they don't really know the “why” here. Could be the food itself, could be pesticides, and until the results are replicated they urge parents not to change their child's diet. https://www.news-medical.net/news/20240909/Eating-fruit-oats-and-rye-in-childhood-may-increase-type-1-diabetes-risk.aspx XX Researchers in France have developed a once-a-month hydrogel-based delivery system for semaglutide, significantly simplifying diabetes and weight management Semaglutide, marketed as Ozempic, Rybelsus, and Wegovy, is a GLP-1 receptor agonist that helps to regulate blood sugar levels and promote weight loss. This medication is especially effective in managing type 2 diabetes and is available in both injectable and oral forms. Semaglutide enhances the body's natural ability to control blood glucose and reduce appetite, providing a dual approach to treatment.     The new hydrogel delivery platform uses two innovative degradable polymers that are chemically bound to one another to form a gel, but allow slow, sustained release of soluble peptides over 1 to 3 months. How do you slow release a gel? With an injection. It goes under the skin. This is still in animal studies, so we're a ways off from human clinical trials. https://scitechdaily.com/new-semaglutide-hydrogel-say-goodbye-to-weekly-shots-for-diabetes-and-weight-loss/ XX   Edgepark Commercial XX   Embecta has received clearance from the Food and Drug Administration for its first insulin patch pump. The device can be used by people with Type 1 or Type 2 diabetes and worn for up to three days. It includes a 300-unit insulin reservoir. Embecta said Tuesday it plans to develop a closed-loop version of the pump for automated insulin dosing that it will submit to the FDA in the future using the Tidepool Loop algorithm. Earlier this summer, Insulet received FDA clearance to offer its Omnipod 5 pump to people with Type 2 diabetes. Diabetes tech firms have focused on Type 2 in recent years as insurance coverage improves. https://www.medtechdive.com/news/embecta-gets-fda-nod-for-insulin-patch-pump/725904/ XX An artificial intelligence (AI)–driven voice algorithm showed "excellent agreement" with the American Diabetes Association (ADA) risk test in detecting adults with type 2 diabetes (T2D), research presented at the European Association for the Study of Diabetes (EASD) 2024 Annual Meeting revealed.   The AI model detected T2D with 66% accuracy among women and 71% in men, and there was 93% agreement with the questionnaire-based ADA risk score, demonstrating comparable performance between voice analysis and an accepted screening tool.   The Colive Voice project includes volunteers from all over the world; however, the current study was restricted to adults from the United States, both with and without T2D, "This first proof of concept was limited to English speakers, and further research will need to enroll more diverse populations, in terms of languages and sociodemographic background," he said. "This study represents a first step toward using voice analysis as a first-line, highly scalable T2D screening strategy," the authors concluded. "The next studies will have to demonstrate the robustness of our approach in diverse populations and also include people living with prediabetes," Fagherazzi said. "If proven reliable, we expect such technology to be available in the next 5-10 years. Then, it could be deployed easily at scale in millions of smartphones worldwide and reduce undiagnosed diabetes cases." https://www.medscape.com/viewarticle/ai-voice-analysis-diabetes-screening-shows-promise-2024a1000ggw XX Join us again soon!

SummaryIn this conversation, Jason and Mindy discuss various topics including trouble sleeping, weight loss drugs, online trolling, different types of naps, and what their friends and family would assume they had done if they were arrested. They also share an inspirational quote and mention their upcoming merchandise on their website.https://www.lowtreestudios.com/https://www.youtube.com/@lowtreestudiosWeight-loss drugs are taking a big bite out of the food business. People taking meds such as Ozempic, Rybelsus and Wegovy — originally developed to treat diabetes — spend less on groceries and have healthier choices in their basket, according to a new study on shopping behaviors. Analytics firm Grocery Doppio found that semaglutide-takers purchase 47% fewer baked goods; 28% less soda and sugary beverages; 17% less booze; and 13% less processed foods. On the other hand, they are buying more healthy foods, thanks reduced appetites and changes to their taste buds. A new study published in Behavioral Sciences determined that those with dark humor are more likely to engage in online trolling. And what's more, they don't appreciate it when their antagonism turned back on them. In other words, trolls don't like being trolled. Online trolling is a social behavior characterized by deception and disruption. A troll tries to incite controversy simply to watch people turn against each other. And now, the doozy: The researchers' findings also indicate that people who possess a dark sense of humor are more likely to demonstrate sadism and Machiavellianism (being cunning, scheming, and unscrupulous).NAP RAPPIN':It's Tuesday. Maybe you were up late watching Olympics or your favorite show. Sounds like a good excuse for a nice nap, right after work. Here are 4 types of naps, and how to choose which one is perfect for you…“Power Nap.” For most, a classic “power nap” of 10-20 minutes in the early afternoon will help them shake off that post-lunch blahs, and feel OK for the rest of the day. This is great if you often feel lethargic for a few hours in the afternoon.“Coffee Nap”: If a short nap isn't much help, try this. Drink a cup of coffee quickly, then lie down. It takes caffeine about 10 minutes to affect you, and about 45 minutes to reach peak concentration in your blood. That means you can get a power nap in, then wake up just as the caffeine hits, giving you an amplified sense of sharpness and clarity. “Convenient Nap”: Scheduling a nap is great, but what if your schedule is all over the place? An imperfect nap is better than no nap at all. Nap when the baby is sleeping, while on public transit, or during your lunch hour. “Performance Nap”: If you have a stressful or physically demanding task coming up, such as a presentation or a marathon, a short nap a few hours ahead of time can definitely boost your performance.

We sit down with Jennifer Jonsson, a patient advocate, to explore the complex world of medication interactions and their impact on mental health. Jennifer shares her personal journey of managing ADHD, bipolar disorder, and Type 2 diabetes while navigating the unexpected side effects of medications like Rybelsus. We discuss the importance of self-advocacy, effective communication with health care providers, and practical strategies for handling multiple chronic conditions. Jennifer Jonsson is a patient advocate. She discusses the KevinMD article, "Can weight loss medication interfere with ADHD meds?" Our presenting sponsor is Nuance, a Microsoft company. Together, Microsoft and Nuance are leveraging their rich digital technology and advanced AI capabilities to tackle some of health care's biggest challenges. AI-driven technology promises to revolutionize patient and provider experiences with clinical documentation that writes itself. The Nuance Dragon Ambient eXperience, or DAX for short, is a voice-enabled solution that automatically captures patient encounters securely and accurately at the point of care. DAX Copilot combines proven conversational and ambient AI with the most advanced generative AI in a mobile application that integrates directly with your existing workflows. Physicians who use DAX have reported a 50 percent decrease in documentation time and a 70 percent reduction in feelings of burnout, and 85 percent of patients say their physician is more personable and conversational. Discover AI-powered clinical documentation that writes itself. Visit https://nuance.com/daxinaction to see a 12-minute DAX Copilot demo. VISIT SPONSOR → https://nuance.com/daxinaction SUBSCRIBE TO THE PODCAST → https://www.kevinmd.com/podcast RECOMMENDED BY KEVINMD → https://www.kevinmd.com/recommended GET CME FOR THIS EPISODE → https://www.kevinmd.com/cme I'm partnering with Learner+ to offer clinicians access to an AI-powered reflective portfolio that rewards CME/CE credits from meaningful reflections. Find out more: https://www.kevinmd.com/learnerplus

Send us a Text Message.https://ro.co/weight-loss/supply-trackerhttps://www.youtube.com/watch?v=mL_krAas70kNovo Nordisk Advertising:Novo Nordisk launches new advertising campaign "The Power of Wegovy"This advertisement includes the new indication for reduction of cardiovascular riskFor 2023, the #5 advertising spend for a drug was Rybelsus at $191 million.  The #6 advertising spend was Ozempic at $187.4 million (increase of 6% from 2022). More than 40% of the 2023 ad spend for Ozempic  went to online video platforms (i.e. social media like youtube)Link: https://www.youtube.com/watch?v=dhretLXYkZ4Structure Therapeutics GSBR-1290GSBR-1290 is a small molecule GLP-1 pillIn a 12-week phase 2 clinical study, a tablet formulation of GSBR-1290 had a weight-loss of 6.9%. This is comparable to Eli Lilly's phase 2 results for olforglipronAt Week 12, 67% of GSBR-1290 treated participants achieved ≥6% weight loss and 33% achieved ≥ 10% weight loss, compared to 0% for placeboAlso developing next generation combination GLP-1 candidates together with GIP, amylin, glucagon and apelin oral small moleculesLink (Madison Muller): https://www.bloomberg.com/news/articles/2024-06-03/structure-reports-early-oral-weight-loss-drug-data-adding-allureElon musk tweet:Elon Musk tweeted: Just make a lot of Ozempic/Mounjaro. It's not inherently expensive. The health benefits of reducing obesity far exceed the downside of GLP-1 inhibitors. We evolved under starving conditions and now make food that is plentiful and delicious. Whether that food is “processed” does matter, but is not a game changerThis tweet has currently been seen 325,500 timesShanghai Stem Cell Type 2 Diabetes Treatmenthttps://www.scmp.com/news/china/science/article/3263878/chinese-scientists-report-world-first-they-cure-patients-diabetes-cell-therapySupport the Show.MY WORK RELIES ON YOUR GENEROSITY, BECOME A MEMBER HERE:https://www.youtube.com/channel/UCDocQ-4IhVS3ihy_dW7nSKw/joinVenmo: OnThePenCa$h App: ManOnMounjaroBECOME A MEMBER HERE:https://www.youtube.com/channel/UCDocQ-4IhVS3ihy_dW7nSKw/joinSOCIAL LINKShttps://www.tiktok.com/@manonthemounjarohttps://twitter.com/ManOnMounjarohttps://instagram.com/manonthemounjarohttps://facebook.com/manonthemounjaro #Zepbound #releasethevials #mounjaro

Neste episódio, conto a minha opinião pessoal sobre as semaglutidas - substâncias presentes em alguns medicamentos, e que estimulam a produção de insulina no corpo - de um modo geral.Vou englobar tudo no mesmo "saco", então, falarei sobre os medicamentos Ozempic, Rybelsus, Wegovy, Monjauro e Tirzpartide por serem variações do mesmo tema.É bom? Para quem e quando? Descubra nesse episódio. Para mais informações sobre esse, e outros assuntos, acesse o meu site https://isabelafortes.com.br/. Para mais dicas, me siga no Instagram https://www.instagram.com/fortes_isabela. Produção: Wepod

Send us a Text Message.1.7 mg of Wegovy is no longer in shortage:Semaglutide: FDA website updated to show 1.7 mg of Wegovy is no longer in shortageLink: https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Semaglutide%20Injection&st=cGNC introduces special section for GLP-1 users:GNC will have special section for GLP-1 users that will concentrate on four areas: GI Health, Retaining Lean muscle mass, Bone health, Nutritional supportLink: https://www.gnc.com/learn/newsroom/gnc-semaglutide-support-program.htmlIdentified upper dose values in tirzepatide high-dose trial20 mg and 25 mgPrimary Completion in this trial is 12/24/2024 (Merry Christmas) with final completion September 30, 2025 Link:  https://www.onthepen.com/post/higher-doses-of-zepbound-and-mounjaro-being-testedUS Senator Bernie Sanders investigating the price of Wegovy/OzempicOzempic costs $936 per month, while Wegovy costs $1,350Ozempic costs $155 in Canada, and cost $59 in Germany. This dramatic difference in cost has led to concerns about the accessibility and affordability of these drugs for American patients.With the cardiovascular disease indication, millions of additional medicare patients are eligible for taking Wegovy which means billions at the current prices Link:  https://www.onthepen.com/post/the-price-of-health-bernie-sanders-investigates-ozempic-and-wegovyLink: https://www.kff.org/medicare/issue-brief/a-new-use-for-wegovy-opens-the-door-to-medicare-coverage-for-millions-of-people-with-obesity/Germany is promoting their pharmaceuticals industry: tax breaks, and speeding up clinical trialsEli Lilly is investing 2.3 Billion Euros to build a glp-1 manufacturing plant in Germany:Link: https://uk.finance.yahoo.com/news/scholz-promises-support-pharma-sector-101833297.htmlLexaria begins phase 1 trial:Lexaria (stock symbol: LEXX) will test their technology to improve stomach absorption of Rybelsus in phase 1 trial (i.e. wouldn't need large 25/50 mg doses if absorption was better). They are also testing under tongue (sublingual) absorption of Rybelsus in another phase 1 trialLink: https://ir.lexariabioscience.com/news-events/press-releases/detail/246/lexaria-receives-ethics-review-board-approval-to-begin-newViking Therapeutics earnings callPlanning to start addition phase 2 trial of injectable VikingTide (VK2735) in Q4 of 2024 that will last 6-9 months (If you remember, the first phase 2 trial was only 13 weeks)The oral VikingTide (VK2735) phase 1 trial is still investigating higher and higher  doses due to the low side effect profile. They expect results in summer of 2024.MY WORK RELIES ON YOUR GENEROSITY, BECOME A MEMBER HERE:https://www.youtube.com/channel/UCDocQ-4IhVS3ihy_dW7nSKw/joinVenmo: OnThePenCa$h App: ManOnMounjaroSOCIAL LINKShttps://www.tiktok.com/@manonthemounjarohttps://twitter.com/ManOnMounjarohttps://instagram.com/manonthemounjarohttps://facebook.com/manonthemounjaroThank you for tuning in! If you found this content valuable, make sure to like, share, and subscribe to my youtube channel for more updates on GLP-1, obesity, type 2 diabetes, and the latest news on Mounjaro, Zepbound, Wegovy, and Ozempic. Stay informed and entertained with my unique blend of breaking news, humor, and my personal journey. For in-depth articles and resources, visit my website at onthepen.com. You can also connect with me on social media, where I go by @manonthemounjaro (or @manonmounjaro on X). Let's continue this journey together towards a healthier and happier life!

What's the best weight loss drug?Is semaglutide safe? What's the difference between Ozempic, Wegovy, and Mounjaro? If you are considering taking one of these new weight loss medications, then this episode is for you. These new “miracle” weight loss drugs are supposedly helping people lose weight like crazy.. Even Oprah recently announced that she was using them to help her lose weight! In this episode, we'll answer the following questions . . . What is semaglutide?What does it do in your body?Does it really help you lose weight? How much weight can you expect to lose from Ozempic or Wegovy? What are the semaglutide side effects?What I've learned from my people who have used it personally.And I'll share my two cents, just my opinion from everything I've seen, heard, and read. Please understand - I am not here to promote or demonize this drug. I just want to provide accurate information - the pros and cons, and then you can decide if this is something you might want to discuss with your doctor. What you do with your body and what you put into your body is 100% your business and your decision. I chose to do this episode, because I know that many of you consider me a trusted source of information in the health and weight loss world. That is a tremendous honor that I do NOT take lightly. So let's dig into this new weight loss drug called semaglutide or the commercial names that you might know - Ozempic, Wegovy, or Rybelsus. 1: JOIN THE INNER CIRCLE: support@CoreyLittleCoaching.com 2: PURCHASE RISE NUTRITION PRODUCTSWebsite: https://challenge2rise.com/Smart Energy: https://challenge2rise.com/product/smart-energy/Elite Omega-3 on Amazon: https://a.co/d/3dgilSGEssential Nutrients on Amazon: https://a.co/d/6rcULakElite Nutrients on Amazon: https://a.co/d/duQn1TDFREE MENOPAUSE DOWNLOAD: http://coreylittlecoaching.com/menopause

Registered Dietician Kathleen Meehan joins me again for a conversation about the hot (and controversial) topic of semaglutide weight loss medications you know as Ozempic, Wegovy, and Rybelsus. We dive into the science of glucose, the often overlooked side effects and risks of these drugs, and the bombardment of marketing at every turn. Find Kathleen: KathleenMeehanRD.com Instagram.com/therdnutritionist Tiktok.com/@kathleenmrdn Don't forget to subscribe to this channel and get all the links you heard about on the show at realeverything.com. Learn more about your ad choices. Visit megaphone.fm/adchoices

Semaglutide, which is sold under the brand names Ozempic, Wegovy and Rybelsus, has become increasingly popular and is a medication you are likely to encounter in the clinical setting and when reviewing your patient's medical histories. In this article, you'll learn the key things to know about semaglutide using the Straight A Nursing DRRUGS framework. In this episode, you'll learn: The principles of the GLP-1 agonist drug class, including their main mechanism of action The two routes of administration The regular dose range for these medications What semaglutides are used to treat and why they work Key guidelines including administration, safety considerations, assessments, and drug-to-drug interactions The potential side effects, including a description of "Ozempic face" and what patients can do to lesson symptoms ___________________ Full Transcript - Read the article and view references FREE CLASS - If all you've heard are nursing school horror stories, then you need this class! Join me in this on-demand session where I dispel all those nursing school myths and show you that YES...you can thrive in nursing school without it taking over your life! Fast Pharmacology - Learn pharmacology concepts in 5 minutes or less in this audio based program. Perfect for on-the-go review! Pharmacology Success Pack - Want to get a head start on pharmacology? Download the FREE Pharmacology Success Pack

Are these new weight loss drugs that are on the market (and seem to be taking the world by storm) all that good for you?    A lot of celebrities and social media influencers are sharing their amazing results after taking weight loos drugs (like Ozempic). This got Dr. Jockers intrigued to learn more. And he's here today to share his findings!   How do these miracle weight loss drugs actually work? Dr. Jockers goes into the physiology as well as the side effects. Learn about how semaglutide medication can give you nausea and other digestive symptoms.    If you're taking this medication long-term, there are other side effects you seriously need to consider too! Make the best informed decision possible by learning from the best functional nutrionist around as Dr. Jockers proves a balanced view on semaglutide medications.    Please join us and please also share this information with someone you think may need it. Thank you.   In This Episode:   What is semaglutide? What is Wegovy and Rybelsus? What do glucagon-like peptide 1 (GLP-1) drugs actually do?  Understanding Advanced glycation end-products (AGEs)  How weight loss drugs increase satiety (leading to weight loss) What are the most common side effects? Understanding the potential of more damaging (rarer) side effects How can we improve our satiety level naturally?  Getting 30g of protein to increase your satiety Why a high protein, high healthy fat diet is the way to go Kick out toxins and boost your metabolism fast with the master of ALL antioxidants – GLUTATHIONE. When supplementing with high-quality glutathione… You will purge unhealthy toxins. You will lose weight with less effort. You will feel more energetic. You will notice a brighter complexion. And, you will feel much healthier overall!   But here's the thing, not all Glutathione supplements are created equal… If you're taking Glutathione in capsule or tablet form, you are missing out on key nutrients as they will simply pass through your body without being absorbed (you can thank your stomach acid for that).   However, my friends over at Purality Health have a NEW rapid-absorbing, delicious glutathione spray that delivers this powerful antioxidant straight to the areas of your body that need it most! Just pump a few sprays onto your tongue and watch as toxins naturally purge from your body.   The best part? You can experience these results in as little as 7 days. For a limited time, they are offering a special buy one get one free deal which is backed by a 180-day money-back guarantee. All you need to do is visit masterantioxidant.com/drj to access this exclusive deal.     Did you know that there's an entire line of teas specifically formulated to enhance the benefits of fasting? It's called Pique Tea and it's the highest quality tea that's out there! It's extracted via cold brew crystallization that gently preserves active compounds at their maximum potential, with no prep or brewing needed!   Pique Tea is also 100% organic and triple toxin screened for pesticides, heavy metals, and toxic mold (really common in tea). Pique Tea is designed to shut down your appetite, reduce cravings, enhance the benefits of fasting, and support healthy weight management.   Check out their range of Fasting teas, featuring Matcha, Cinnamon, Ginger, and Bergamot Fasting tea crystals. These teas are also organic, non-GMO, and gluten free!  For a limited time get up to 20% off plus two free gifts. Simply follow the link to piquelife.com/jockers to get 20% off your fasting teas!     “There's no miracle drug out there. So any drug you're gonna take is gonna have side effects." - Dr. Jockers.   Subscribe to the podcast on: Apple Podcast Stitcher Spotify PodBean  TuneIn Radio   Resources: piquelife.com/jockers - Get 20% off your fasting teas, plus two free gifts! Check out Glutathione Spray at masterantioxidant.com/drj - Backed by a 180-day money-back guarantee!   Connect with Dr. Jockers: Instagram – https://www.instagram.com/drjockers/ Facebook – https://www.facebook.com/DrDavidJockers YouTube – https://www.youtube.com/user/djockers Website – https://drjockers.com/ If you are interested in being a guest on the show, we would love to hear from you! Please contact us here! - https://drjockers.com/join-us-dr-jockers-functional-nutrition-podcast/  

John lists off all the things to be grateful for in 2023. Then, he interviews freelance writer for Fast Company - Adam Bluestein on the success of diabetes/weight loss drugs like Ozempic and Rybelsus. Then, year end calls from listeners: Steve in L.A., Laurie in Florida, Dave in Pittsburg, Rachel in L.A., and Stephen in Kentucky.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.